US20080021385A1 - Loading and release of water-insoluble drugs - Google Patents

Loading and release of water-insoluble drugs Download PDF

Info

Publication number
US20080021385A1
US20080021385A1 US11/833,717 US83371707A US2008021385A1 US 20080021385 A1 US20080021385 A1 US 20080021385A1 US 83371707 A US83371707 A US 83371707A US 2008021385 A1 US2008021385 A1 US 2008021385A1
Authority
US
United States
Prior art keywords
catheter
drug
polymer
paclitaxel
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/833,717
Inventor
James Barry
Maria Palasis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Scimed Inc
Original Assignee
Boston Scientific Scimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US91013697A priority Critical
Priority to US13360398A priority
Priority to US09/172,026 priority patent/US6306166B1/en
Priority to US09/978,763 priority patent/US20020037358A1/en
Priority to US11/188,850 priority patent/US20060002973A1/en
Application filed by Boston Scientific Scimed Inc filed Critical Boston Scientific Scimed Inc
Priority to US11/833,717 priority patent/US20080021385A1/en
Assigned to BOSTON SCIENTIFIC SCIMED, INC. reassignment BOSTON SCIENTIFIC SCIMED, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SCIMED LIFE SYSTEMS, INC.
Publication of US20080021385A1 publication Critical patent/US20080021385A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22626067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080021385(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M25/1027Making of balloon catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00Dilators with or without means for introducing media, e.g. remedies
    • A61M29/02Dilators made of swellable material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222Steroids, e.g. corticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45Mixtures of two or more drugs, e.g. synergistic mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • A61L2300/604Biodegradation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0043Catheters; Hollow probes characterised by structural features
    • A61M2025/0057Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/105Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/1075Balloon catheters with special features or adapted for special applications having a balloon composed of several layers, e.g. by coating or embedding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/1081Balloon catheters with special features or adapted for special applications having sheaths or the like for covering the balloon but not forming a permanent part of the balloon, e.g. retractable, dissolvable or tearable sheaths
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/1088Balloon catheters with special features or adapted for special applications having special surface characteristics depending on material properties or added substances, e.g. for reducing friction

Abstract

A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Description

  • This application is a continuation of co-pending application Ser. No. 09/172,026 filed Oct. 14, 1998, which is a continuation-in-part of co-pending application Ser. No. 09/133,603, filed Aug. 13,1998, which is a continuation-in-part of co-pending application Ser. No. 08/910,136, filed Aug. 13, 199.7, all of which are incorporated herein in their entirety by reference thereto.
  • FIELD OF THE INVENTION
  • The invention relates to methods and devices for the localized delivery of substantially water-insoluble drug agents within the body.
  • BACKGROUND
  • The systemic administration of drug agents, such as by transoral or intravenous means, treats the body as a whole even though the disease to be treated may be localized. In such a case, systemic administration may not be desirable because, for example, the drug agents may have unwanted effects on parts of the body which are not to be treated, or because treatment of the diseased part of the body requires a high concentration of drug agent that may not be achievable by systemic administration.
  • It is therefore often desirable to administer drug agents at a localized site within the body. Common examples include cases of localized disease or occluded body lumens. Various methods have been proposed for such localized drug administration. For example, U.S. Pat. No. 5,304,121, hereby incorporated by reference, discloses a method of delivering water-soluble drugs to tissue at desired locations of a body lumen wall. The method generally includes the steps of impregnating a hydrogel polymer on an expandable catheter with an aqueous drug solution, inserting the catheter into a blood vessel to a desired location, and expanding the catheter against the surrounding tissue allowing the release of the drug to the tissue. This method of localized drug delivery using hydrogel polymer impregnation. has a limitation of being applicable to drug agents which are dissolved in water at concentrations sufficient for therapeutic gel loading levels. There thus exists a need for a method and apparatus for the localized delivery of drug agents within the body, where the drug agents are substantially water-insoluble. Moreover, there exists a need for a method and implantable device that provides a sustained release of such substantially water-insoluble drug agents over a time frame effective to inhibit proliferative disease.
  • SUMMARY OF THE INVENTION
  • One objective of the present invention is to provide a method and apparatus for the localized delivery of substantially water-insoluble drug agents to predetermined locations within the human body.
  • A further objective of the present invention is to provide a method and apparatus to facilitate gradual, localized release of drug agents at predetermined locations within the human body.
  • A further objective of the invention is to administer drug agents by. diffusion directly into the tissue requiring treatment. The drug is preferably applied in a manner that does not further injure the tissue to be treated, and administration is selectively and evenly distributed over the treated area such that the drug can be taken up by the tissue, without, for example, being washed away by body fluids.
  • The present invention provides methods and medical devices for the localized delivery of substantially water-insoluble drugs agents.
  • A particular embodiment of the present invention features a catheter and method for delivering substantially water-insoluble drug agents to tissue at a desired location along body lumen walls. The catheter is constructed for insertion in a body lumen and has a catheter shaft and an expandable portion mounted on the catheter shaft. The expandable portion is expandable to fill the cross-section of the body lumen. At least a portion of the exterior surface of the expandable portion is defined by a polymer coating. Incorporated into the polymer coating is at least one substantially water-insoluble drug. The catheter is positioned to a desired target location within the body, whereupon the. polymer coating absorbs water, thus dissolving the drug and resulting in the diffusion of the drug out of the polymer coating. The polymer and drug are selected to allow controlled release of a desired dosage of the drug from the polymer.
  • Another particular embodiment of the present invention features a stent for the localized delivery of substantially water-insoluble drug agents to tissue at a desired location along body lumen walls. The stent is at least partially coated with a polymer coating having at least one substantially water-insoluble drug therein. The stent configuration, polymer and drug are selected to allow for the controlled release dosage and release rate of the drug from the polymer.
  • In a most preferred embodiment, the stent is a patterned stent for the localized delivery of paclitaxel to tissue at a desired location along body lumen walls. The stent is at least partially coated with a polymer/paclitaxel matrix that provides sustained release of paclitaxel at the desired site within the lumen wall.
  • In another aspect of the invention, there is provided a method for preventing or inhibiting proliferative disease in a patient comprising implanting a patterned stent comprising an outer coating of polymer/paclitaxel at a site of cellular proliferation, wherein the paclitaxel is released from the outer coating at a release rate and for a period of time sufficient to inhibit or prevent cellular proliferation at the site.
  • BRIEF DESCRIPTION OF THE DRAWING
  • FIG. 1 a shows one embodiment of the present invention in which a drug solution is impregnated into a polymer-coated balloon catheter.
  • FIG. 1 b shows the insertion of a polymer-coated balloon catheter into a body lumen, in accordance with the present invention.
  • FIG. 1 c shows the expansion of a polymer-coated balloon catheter at an occlusion site within a body lumen, in accordance with the present invention.
  • FIG. 2 shows a drug delivery balloon catheter embodiment of the present invention including a sheath for covering the catheter as it is being moved through a vessel toward the occlusion to be treated.
  • FIGS. 3 a and 3 b show the release profile of paclitaxel from a balloon catheter having a polyacrylic acid-based coating for up to 50 and 5000 minutes, respectively, in accordance with the present invention.
  • FIGS. 4 a and 4 b show the release profile of dexamethasone from a balloon catheter having a polyacrylic acid-based coating for up to 30 and 400 minutes, respectively, in accordance with the present invention.
  • FIG. 5 shows the release profiles of molsidomine from various balloon catheters having a polyacrylic acid-based coating for up to 5 minutes, in accordance with the present invention.
  • FIG. 6 shows the release profiles of dexamethasone from various balloon catheters having a polyacrylic acid-based coating for up to 450 minutes, in accordance with the present invention.
  • FIGS. 7 a and 7 b show the release profiles of water-soluble and substantially water-insoluble estradiol from balloon catheters having a polyacrylic acid-based coatings for up to 10 and 200 minutes, respectively, in accordance with the present invention.
  • FIG. 8 shows the release profile of paclitaxel for up to 10 days from polyurethane coated stents dipped in 30 mg/ml paclitaxel in ethanol for 3 days, in accordance with the present invention.
  • FIG. 9 shows the release profiles of paclitaxel from various polyurethane-coated balloon catheters for up to 2 hours, in accordance with the present invention.
  • FIG. 10 shows the cumulative release profile of paclitaxel over a time frame of days. This figure shows the cumulative release of paclitaxel for delivery rates of 5 μg/day and 0.5 μg/day.
  • DETAILED DESCRIPTION
  • The present invention provides methods and medical devices for the localized delivery of one or more substantially water-insoluble drug agents to predetermined locations within the human body, such as within the vascular system, urinary tract, prostate, esophagus, colon, brain, etc.
  • In accordance with an embodiment of the invention, a substantially water-insoluble drug agent is dissolved in a volatile organic solvent. “Organic solvent” is intended to mean a singular organic solvent or a solvent mixture having at least one organic component. The solvent mixture also includes mixtures of water with miscible organic solvents. The drug solution is then applied to a polymer coating on a medical device that is adapted for insertion into the body. Examples of such medical devices include catheters, guide wires, balloons, filters (e.g., vena cava filters), stents, stent grafts, vascular grafts, intraluminal paving systems, implants and other devices used in connection with drug-loaded polymer coatings. Such devices are implanted or otherwise utilized in body lumina and organs such as the coronary vasculature, esophagus, trachea, colon, biliary tract, urinary tract, prostate, brain, and the like. Examples of suitable vascular grafts are described in U.S. Pat Nos. 5,509,931, 5,527,353, and 5,556,426. Vena cava filters such as those described in WO 96/12448 and WO 96/17634 may also be used in the present invention. All of foregoing documents identified by number are incorporated herein in their entireties.
  • The filters that can be provided with a polymeric material/drug-agent matrix in accordance with the present invention include, for example, thrombus filters that can be placed at a selected location within the vascular system and removed when no longer required. A preferred location for placement of these filters is the vena cava. Filters placed in the vascular system can intercept blood clots that may otherwise travel to the lungs and result in a pulmonary embolism, a life-threatening emergency that has become increasingly common. In one embodiment of the present invention there is provided such an implanted vascular filter having a polymeric material/drug outer coating thereon. In a most preferred embodiment, the filter has a polymeric material/paclitaxel outer coating, and most preferably, a polylactic acid/polycaprolactone copolymer/paclitaxel coating. The polymeric coating may also have incorporated therein or thereon any other therapeutic agent that is used for reducing the formation of, or complications due to, clot formation or neointima formation. Such agents, include, but are not limited to antithrombogenic agents and thrombolytic agents and other antiproliferative agents.
  • Further examples of filters that may be provided with the polymeric material/drug coating in accordance with present invention include, e.g., those described in International Application No. WO 96/17634 and International Application No. WO 96/12448, both of which are herein incorporated by reference.
  • The grafts, including stent grafts, that can be provided with a polymeric material/drug agent matrix in accordance with the present invention include synthetic vascular grafts that can be used for replacement of blood vessels in part or in whole. A typical vascular graft is a synthetic tube with each end thereof sutured to the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. In a typical stent graft, each end of the synthetic tube portion includes a stent that is affixed to each of the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. Alternatively, in a stent graft, the replacement vessel may be segment of a vessel removed from another location in the patient, such as a portion of a femoral artery or the like. In the case of a synthetic graft, the graft is typically tubular and may be, e.g., of a woven, knit or velour construction. Preferred materials for the grafts and covering material for the stent grafts include polyethylene terephthalate and polytetrafluoroethylene. The vascular grafts may be reinforced with, for example, helices, rings, etc. in order to provide uniform strength over the entire surface of the graft tubing. The materials of which such grafts are constructed are biologically compatible materials including, but not limited to, thermoplastic materials such is as polyester, polytetrafluoroethylene (PTFE), silicone and polyurethanes. The preferred materials include polyester fibers and PTFE.
  • Examples of other suitable grafts are described in U.S. Pat. Nos. 5,509,931, 5,527,353, and 5,556,426, all of which are herein incorporated by reference. In a most preferred embodiment of the invention, the graft is provided with a coating of polymeric material/paclitaxel, and most preferably, the polymeric material is a copolymer of polycaprolactone and polylactic acid. This paclitaxel-coated graft, when positioned at a desired site in the body provides an extended release of paclitaxel to the site.
  • A polymeric material/drug agent matrix in accordance with the present invention may be used as an intraluminal paving system. In such intraluminal paving systems as are known in the art, the polymeric material/drug agent matrix will typically be applied directly to an interior surface of vascular or non-vascular lumina. An intraluminal paving system is formed, for example, by admixing a drug agent with a liquid polymer, in the absence of a solvent, to form a liquid polymer/drug agent mixture. The mixture is then applied directly to a luminal surface by any conventional method, such as by injecting the mixture against the luminal surface. Curing of the mixture typically occurs in-situ. To facilitate curing, a cross-linking or curing agent may be added to the mixture prior to application thereof to the luminal surface. Addition of the cross-linking or curing agent to the polymer/drug agent liquid mixture must not occur too far in advance of the application of the mixture to the luminal surface in order to avoid over-curing of the mixture prior to application thereof to the luminal surface. Curing may also occur in-situ by exposing the polymer/drug agent mixture, after application to the luminal surface, to radiation such as ultraviolet radiation or laser light, heat, or by contact with metabolic fluids such as water at the site where the mixture has been applied to the luminal surface. In a preferred intraluminal paving system in accordance with the invention, the drug agent is paclitaxel and the paclitaxel may be incorporated in the polymeric material alone or in combination with another drug agent. In intraluminal paving systems in accordance with a preferred embodiment of the present invention, the polymeric material incorporating the paclitaxel and, if desired, any additional therapeutic agent(s), may be either bioabsorbable or biostable. Any of the polymers described herein that may be formulated as a liquid may be used to form the polymer/drug agent mixture for use as an intraluminal paving system.
  • In a preferred embodiment, the polymer used to coat the medical device is provided in the form of a coating on an expandable portion of a medical device. After applying the drug solution to the polymer and evaporating the volatile solvent from the polymer, the medical device is inserted into a body lumen where it is positioned to a target location. In the case of a balloon catheter, the expandable portion of the catheter is subsequently expanded to bring the drug-impregnated polymer coating into contact with the lumen wall. The drug is released from the polymer as it slowly dissolves into the aqueous bodily fluids and diffuses out of the polymer. This enables administration of the drug to be site-specific, limiting the exposure of the rest of the body to the drug.
  • The polymer used in the present invention is preferably capable of absorbing a substantial amount of drug solution. When applied as a coating on a medical device in accordance with the present invention, the dry polymer is typically on the order of from about 1 to about 50 microns thick. In the case of a balloon catheter, the is thickness is preferably about 1 to 10 microns thick, and more preferably about 2 to 5 microns. Very thin polymer coatings, e.g., of about 0.2-0.3 microns and much thicker coatings, e.g., more than 10 microns, are also possible.
  • It is also within the scope of the present invention to apply multiple layers of polymer coating onto a medical device. Such multiple layers are of the same or different polymer materials.
  • The polymer of the present invention is hydrophilic or hydrophobic, and is selected from the group consisting of polycarboxylic acids, cellulosic polymers, including cellulose acetate and cellulose nitrate, gelatin,. polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyanhydrides including maleic anhydride polymers, polyamides, polyvinyl alcohols, copolymers of vinyl monomers such as EVA, polyvinyl ethers, polyvinyl aromatics, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters including polyethylene terephthalate, polyacrylamides, polyethers, polyether sulfone, polycarbonate, polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene, halogenated polyalkylenes including polytetrafluoroethylene, polyurethanes, polyorthoesters, proteins, polypeptides, silicones, siloxane polymers, polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate valerate and blends and copolymers thereof as well as other biodegradable, bioabsorbable and biostable polymers and copolymers. Coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.) and acrylic latex dispersions are also within the scope of the present invention. The polymer may be a protein polymer, fibrin, collage and derivatives thereof, polysaccharides such as celluloses, starches, dextrans, alginates and derivatives of these polysaccharides, an extracellular matrix component, hyaluronic acid, or another biologic agent or a suitable mixture of any of these, for example. In one embodiment of the invention, the preferred polymer is polyacrylic acid, available as HYDROPLUS® (Boston Scientific Corporation, Natick, Mass.), and described in U.S. Pat. No. 5,091,205, the disclosure of which is hereby incorporated herein by reference. U.S. Pat. No. 5,091,205 describes medical devices coated with one or more polyisocyanates such that the devices become instantly lubricious when exposed to body fluids. In a most preferred embodiment of the invention, the polymer is a copolymer of polylactic acid and polycaprolactone.
  • By “substantially water-insoluble drug” is meant any therapeutic agent having a greater solubility in organics than in water. More specifically, such drugs have a water solubility of no greater than 1 part drug to 30 parts water, more typically no greater than 1 part drug to 1,000 parts water. Such solubilities are described as “sparingly soluble” to “very slightly soluble” in the art.
  • The drug agents used in the present invention are selected from a number of drug types depending on the desired application. For example, these drugs include anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, and analogues thereof; antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, thymidine kinase inhibitors, and analogues thereof; anesthetic agents such as lidocaine, bupivacaine, ropivacaine, and analogues thereof; anti-coagulants; and growth factors.
  • The drug agents useful in accordance with the present invention may be used singly or in combination. For example, an anti-proliferative agent such as paclitaxel may be used in combination with another drug agent, such as an anticoagulant, anti-inflammatory, antithrombogenic, thrombolytic, nitric oxide-containing polymer, or a vascular cell promoter such as VEGF, for example.
  • Paclitaxel is a preferred drug agent for use in accordance with the present invention either alone or in combination with another drug agent, as described above. Paclitaxel is a complex alkaloid extracted from the Pacific Yew Taxusbrevifolia Family (Family Taxacea) which has been demonstrated to have antiproliferative activity. As used herein, paclitaxel includes the alkaloid and any pharmacologically active derivative or analog thereof. Thus paclitaxel includes naturally occurring forms and derivatives thereof and synthetic and semi-synthetic forms thereof. TAXOL® is a commercially available form of paclitaxel.
  • In accordance with the present invention, the drug agents are dissolved in a volatile organic solvent such as, for example, ethanol, isopropanol, chloroform, acetone, pentane, hexane, or methylene chloride, to produce a drug solution. In the case of paclitaxel the preferred solvent is chloroform. The drug solution is then applied to the polymer. A volatile organic solvent typically is selected to provide drug solubilities much greater than the corresponding aqueous solubility for the substantially water-insoluble drug. Accordingly, application of the drug solution to the polymer often results in drug loadings that are orders of magnitude greater than loadings that can be achieved by application of a saturated aqueous solution of the drug to the polymer.
  • The drug solution. is applied to the polymer coating by any suitable means, including dipping the polymer coating into the drug solution or by applying the solution onto the coating such as by pipet or by spraying, for example. In the former method, the amount of drug loading is controlled by regulating the time the polymer is immersed in the drug solution, the extent of polymer cross-linking, the concentration of the drug in the solution and/or the amount of polymer coating. In another embodiment of the invention, the drug is incorporated directly into the polymer prior to the application of the polymer topcoat as a coating onto a medical device.
  • After applying the drug solution to the polymer coating, the volatile solvent is evaporated from the coating, for example, by drying in air or in an oven.
  • The release profile of the drug from the polymer coating is determined by many factors including the drug solubility, amount of drug applied and the thickness and porosity of the polymer coating.
  • In a preferred embodiment of the present invention, one or more additional layers may be applied over at least a portion of a medical device previously coated with a polymer/drug agent in accordance with the present invention. Desirably, such an additional layer will be provided to modify or modulate the release of one or more of the drug agents in the underlying layer. For example, a polymeric coating may be applied over the previously applied polymer/drug agent coating to modulate the release rate of the drug agent in that layer. This additional release rate-modifying or modulating layer may be applied in a subsequent coating step in a manner similar to that disclosed herein, for example by spraying a polymer solution onto the previously applied coating layer or by dipping the previously coated medical device into a solution of the polymer selected to form the modifying or modulating layer. However, other methods for applying polymeric materials to substrates, including, for example, in-situ polymerization methods such as plasma polymerization may also be used to provide the additional release rate-modifying or modulating polymeric layer. Such other application processes included within the scope of the present invention are those that will not detrimentally affect the previously applied layer, including the drug agent(s) incorporated therein or thereon. The additional layer may also include one or more additional drug agents including any of the drug agents incorporated into the underlying polymer/drug agent coating layer. Prior to application of the modifying or modulating layer, any conventional adhesion promotion agent may be applied to the previously applied coating, or other treatment thereof may be conducted, in order to promote adhesion of the modifying or modulating layer to the previously applied coating. Where the modifying or modulating layer is applied in a manner similar to the underlying layer, the polymeric material used for the modifying or modulating layer can be any of the polymers described herein. Where such polymeric material is applied, for example, by plasma polymerization, the polymers are those that can be formed by monomers in a gas phase that can be activated for example by radio frequency waves. Such monomers include, for example, silicone-based monomers such as cyclic or acyclic siloxanes, silanes, silylimidazoles; fluorine-based monomers such as hydrofluorocarbons; aliphatic or aromatic hydrocarbons; acrylic monomers; and combinations thereof. The monomer gas may have functional groups that facilitate later attachment of drug agents thereto by covalent bonding, for example. Any appropriate polymer for the modifying or modulating layer is preferably selected to have a porosity that provides the modifying or modulating effect as described above. The porosity of this polymeric material may also be modified by addition of porosigens or other porosity-effecting adjuvants that are conventionally added to polymers for this purpose. Other factors guiding the selection of a modulating or modifying polymer include, but are not limited to, the thickness of coating layer, the tortuosity of the polymeric material affecting the path of resistance to drug mobility within the polymeric material, the cross-linking density, drug solubility in the modulating or modifying layer, etc. The thickness of the modifying or modulating layer will preferably be less than 5,000 Å, and more preferably in the range of from about 50-2000 Å. A preferred modifying or modulating polymer in accordance with the present invention is a siloxane polymer formed, for example, by a plasma polymerization process. This siloxane modifying or modulating polymer is preferably applied to a medical device that has a polyurethane/drug agent coating previously applied thereto in accordance with the present invention.
  • When an expandable member such as a balloon catheter is used to administer the drug, pressure can be used to increase the rate of drug transfer to the tissue. An increase in pressure increases the diameter of the balloon and therefore the diameter of the surrounding tissue, thereby increasing the surface area for drug transfer. The amount of drug that is delivered per unit time is therefore increased.
  • When an expandable catheter is chosen as the medical device of the present invention, the expandable portion is preferably a balloon, in which case the drug is placed in the polymer for controlled release of the drug upon expansion of the balloon against a body lumen. The expandable portion optionally includes a stent, mountable in a body lumen by expansion thereof. The catheter also optionally comprises a sheath member which is extendable over the expandable portion to inhibit release of the drug into body fluids during placement of the catheter.
  • Referring now to FIGS. 1 a-1 c, an embodiment for the localized delivery of substantially water-insoluble drugs to a predetermined location within the body is described. The drug administration method shown in FIGS. 1 a-1 c illustrates the use of the present invention in conjunction with an angioplasty process. Catheter device 1 comprises a body 3 having a balloon 4 attached at its distal end. The balloon 4 on the catheter 3 includes a polymer coating 6. As shown in FIG. 1 a, drug solution 8 is impregnated into the polymer coating with the balloon in its substantially deflated state prior to insertion into the patient. As shown in FIG. 1 b, after the volatile solvent is evaporated, the device 1 is inserted into a body lumen 2 having a region to be treated, such as an occlusion due to a deposition of plaque 5 on the lumen wall tissue 9. The device 1 is moved along the vessel to position the balloon 4 at the occlusion site, as shown in FIG. 1 c. The lumen. may be, for example, a narrow, tortuous opening through which the catheter is passed by torquing or other known techniques. As shown in FIG. 1 c, the balloon is inflated to provide close contact between the drug-impregnated polymer coating 6 and the surrounding plaque and tissue. As water from the body penetrates into the polymer coating 6, it begins to dissolve the drug agent, which subsequently diffuses out of the polymer coating 6 and into the surrounding plaque and tissue.
  • During drug administration, a substantial amount of the drug contained in the polymer coating is diffused into the affected area. The inflation pressure needed to expand the balloon catheter and dilate the lumen, if necessary, is typically in the range of about 1 to 20 atm. The balloon is formed of any suitable materials such as vinyl polymers such as polyethylene; polyesters such as polyethylene terephthalate;. polyamides such as nylon; polyolefins and copolymers thereof (e.g., Selar, Pebax, Surlyn, Hytrel, etc.). The balloon is optionally a perfusion balloon, which allows blood to perfuse the catheter to prevent ischemia during delivery. A perfusion balloon is particularly preferred for long arterial delivery times and when the delivery drug is only very slightly soluble in water.
  • Referring to the embodiment of the invention illustrated in FIG. 2, the balloon portion 4 of catheter 3 is optionally covered by a protective sheath 7 while the instrument 1 is inserted into a body lumen 2 and positioned at a treatment region. As the coated balloon 4 is positioned at occluded site 5, the protective sheath 7 is drawn back to expose the balloon 4. In an alternative embodiment, the sheath remains stationary while the catheter moves the coated balloon forward into the occluded region. The sheath 7 protects the coating and inhibits premature release of the drug. Such a sheath might be particularly advantageous when using drugs which are not sufficiently water-insoluble or if even minor delivery to tissue during catheter placement is a problem, e.g. for extremely toxic drugs.
  • Although FIGS. 1 and 2 illustrate the application of the present invention to an angioplasty process, the present invention is also used to administer drug agents to target locations where there is no occlusive formation.
  • In other embodiments, the medical device of the present invention is an implantable medical device such as a stent, covered stent, stent graft, intraluminal paving system, wire guide, cannulae, artificial limbs, joints, and other prosthetic devices. Where a stent is used it may either balloon- or self-expandable, and is constructed of any biocompatible material. The grafts and covering materials for the stent grafts are made of any biocompatible material such as, for example, polyurethane, polyesters,. silicone, or polytetrafluoroethylene.
  • Stents are generally configured in one of two configurations: patterned or coil. Coil-type stents include, for example, wire stents in the form of coils, spirals or the like, with or without spines, an example of which is the subject of U.S. Pat. No. 4,886,062 (incorporated herein by reference), another example of which is the GR-II® (Cook Inc.) stent. Patterned stents used in accordance with a most preferred embodiment of the invention include all stents other than coil-type stents such as, for example, slotted tube stents, criss-cross tubular stents, braided stents, hexagonal stents, nets, articulated stents, and the like. Patterned stents are also generally preferred over coil stents because they provide more radial support for surrounding body lumina. Preferred patterned stents for use in the present invention include the NIR™ and RADIUS™ stents (SCIMED Life Systems, Inc.) as described in U.S. Pat. No. 5,733,303 and WO 96/26689 (both of which are incorporated herein by reference); the WALLSTENT® (Schneider Inc.) as described in U.S. Pat. Nos. 4,655,771 and 5,061,275 (both of which are incorporated herein by reference); and the SYMPHONY® stent (Boston Scientific Corp.) as described in U.S. Pat. No. 5,540,712 (incorporated herein by reference). The stents and stent grafts described in U.S. Pat. Nos. 5,766,237, 5,681,356, 5,522,881 and 5,776,180 (each of which is incorporated herein by reference) and the polymer stents described in U.S. Pat. No. 5,769,883 (incorporated herein by reference) are also within the scope of the present invention.
  • The implantation of a stent, stent graft, vascular graft or filter in accordance with the present invention can be conducted by any medical procedure conventionally used for such implantation. In the case of a stent, a polymer/paclitaxel coated stent in accordance with the present invention can be fitted over the inflatable element of a balloon catheter and expanded by the balloon to force the stent into contact with the body lumen at or near a site of injury such as, for example, within an injured blood vessel.
  • Where the medical device in accordance with the present invention is, e.g., a catheter, stent, graft, filter, etc., or any other device used in the vascular system, any blood vessel including arteries, veins and capillaries may be treated in accordance with the present invention. These blood vessels may be in or near any organ in the human or mammalian body.
  • In a most preferred embodiment of the invention, a patterned stent having a polymer/paclitaxel coating is used to prevent or inhibit proliferative disease. As used herein, “proliferative disease” means any disease or disorder including cancers, malignancies, benign growths and other conditions that result from hyperactivity or hyperplasia of somatic cells, and includes restenosis and vascular hyperplasia such as neointimal hyperplasia. Such proliferative diseases may occur in vascular and other luminal or non-luminal regions of the body.
  • The inventors have surprisingly found that extended drug release of paclitaxel from a polymer coating on a patterned stent is obtained and consequently, a significant reduction in neointima formation results. The reduction in neointima formation obtained with patterned stents used in accordance with the present invention is surprisingly superior to that obtained using a coiled stent coated with a polymer/paclitaxel matrix. FIG. 10 shows the release rate of paclitaxel obtained with a stent in accordance with the present invention. In a preferred embodiment, paclitaxel is released from a polymer/paclitaxel coated stent for a time period of at least about 28 days after implantation of stent at the desired location within the body. The patterned stent is coated with an outer coating of polymer/paclitaxel such that the amount of paclitaxel is sufficient to prevent, decrease, eliminate or modify cellular proliferation associated with proliferative disease or disorder. The amount of paclitaxel sufficient to inhibit or prevent proliferative disease will vary according to the size of the patterned stents, but is generally in the range of from about 50 μg to 500 μg per stent.
  • Procedures for preparing a drug delivery medical device with a polymer coating are presented in the following non-limiting examples.
  • EXAMPLE 1 Release Kinetics of Paclitaxel from Polyacrylic Acid-Based Coating
  • A 2 mg/ml solution of paclitaxel is prepared in chloroform. The solution is gently agitated until the paclitaxel is completely dissolved. The solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating and inflated to 2 atm. A total of 100 μl of solution, and hence 200 μg of paclitaxel, is applied to the catheter. The balloon catheter is then dried in air for 30 minutes and in a vacuum oven for 48 hours at 50° C. to evaporate the chloroform. The catheter is then immersed in a solution of 1% dimethyl sulfoxide (DMSO) and phosphate buffered saline(PBS) having a pH of 7.4 for in-vitro drug release. The cumulative amount of paclitaxel released from the catheter coating yields the data shown in FIGS. 3 a and 3 b.
  • EXAMPLE 2 Release Kinetics of Dexamethasone from Polyacrylic Acid-Based Coating
  • Solutions containing 1.5 mg/ml and 200 μg/ml of dexamethasone in chloroform, are prepared by gently agitating until the dexamethasone is completely dissolved. The solutions are separately applied via dripping to separate balloon catheters having polyacrylic acid-based coatings and inflated to 2 atm. A total of 100 μl of each solution is applied to each respective catheter, corresponding to dexamethasone loadings of 1.5 mg and 200 μg, respectively. These results can be contrasted with the inability to apply substantial amounts of dexamethasone to polyacrylic acid-based coatings using aqueous solutions, in which case only about 1 μg of dexamethasone can be loaded into such coatings. The balloon catheters are then dried in a vacuum oven for 2 hours at 50° C. to evaporate the chloroform solvent. The catheters are thereafter immersed in PBS (pH=7.4) to track the release of dexamethasone over time. The cumulative amount of dexamethasone released from each catheter yields the data shown in FIGS. 4 a and 4 b.
  • EXAMPLE 3 Release Kinetic of Molsidomine from Polyacrylic Acid-Based Coating
  • Various solutions of molsidomine in volatile solvents are prepared and applied to balloon catheters by the methods indicated in Table I. In the “dip” application technique, each balloon catheter having a polyacrylic acid-based coating is dipped into its respective solution for 10 minutes. In the “pipet” application technique, 200 μl of solution is pipetted onto its respective coated balloon catheter while slowly turning. All samples are dried in an oven for 30 minutes at 50° C. and thereafter immersed in PBS (pH=7.4) to track the release of molsidomine over time. The cumulative amount of molsidomine released from each catheter yields the data shown in FIG. 5 a and 5 b.
    TABLE I
    Molsidomine solution characterization, and methods of
    applying molsidomine solution to polymer coated catheters.
    Concentration (mg
    Molsidomine per ml Application
    Sample Solvent solvent) technique
    1 chloroform 150 dip
    2 chloroform 30 pipet
    3 chloroform 150 pipet
    4 ethanol 30 pipet
    5 ethanol 30 dip
  • EXAMPLE 4 Release Kinetics of Dexamethasone added to Polyacrylic Acid-Based Topcoat Formulation
  • Rather than forming a solution of dexamethasone in an organic solvent and then applying this solution to polymer-coated balloon catheters as in Example 2, dexamethasone is added directly to the polymer used to coat the balloon catheters. Dexamethasone is weighed out into 0.05 g, 0.1 g, and 0.2 g samples, each of which is each added to 1 ml lots of polymer topcoat solution containing polyacrylic acid, methyl ethyl ketone, dimethyl formamide, and t-butyl alcohol. The dexamethasone samples are mixed with the polymer topcoat solutions until completely dissolved. The dexamethasone-containing polymer topcoat solutions are separately applied via dripping to separate, uncoated balloon catheters inflated to 2 atm. After drying in a vacuum oven for 2 hours at 50° C., the catheters are immersed in PBS (pH=7.4) to track the release of dexamethasone over time. The cumulative amount of dexamethasone released from each catheter yields the data shown in FIG. 6.
  • EXAMPLE 5 Comparative Release Kinetics for Water-Soluble and Water-Insoluble Estradiol
  • Estradiol is provided in both water-soluble and substantially water-insoluble forms. Water-soluble estradiol is applied to a balloon catheter coated with a polyacrylic acid-based coating by i) preparing a 10 mg/ml solution of water-soluble estradiol in deionized, ultra-filtered water; and ii) placing the balloon catheter, inflated to 2 atm, into 200 μl of the solution for 20 minutes. Water-insoluble estradiol is applied to a balloon catheter coated with a polyacrylic-acid based coating by i) preparing a 10 mg/ml solution of substantially water-insoluble estradiol in methanol; and ii) dripping 100 A1 of the solution onto the balloon catheter. The catheters are thereafter immersed in PBS (pH=7.4) to track the release of both water-soluble and water-insoluble estradiol over time. Greater release is observed for the substantially water-insoluble form of estradiol when compared to the water-soluble form. The cumulative amount of estradiol released from each catheter yields the data shown in FIGS. 7 a and 7 b.
  • EXAMPLE 6 In-vivo Delivery of Paclitaxel from Polyacrylic Acid-Based Coating
  • A 9.8 mg/ml solution of radio-labeled paclitaxel in chloroform is prepared. A total of 50 μl of the solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating. The paclitaxel from the coated balloon catheter is then released in-vivo to porcine arteries. After release for a predetermined amount of time, the paclitaxel remaining in the coating is extracted using two sequential ethanol washes. The amount of paclitaxel released in the pig bloodstream, as calculated from the amount of paclitaxel loaded into the coating minus that extracted from the coating after delivery, is shown in Table II.
    TABLE II
    Amount of paclitaxel released into pig bloodstream from
    an impregnated, polyacrylic acid-based coated balloon
    catheter, as a function of delivery time.
    Amount of Amount of
    paclitaxel paclitaxel % of
    Amount of extracted from released in paclitaxel
    time in balloon after bloodstream released in
    bloodstream delivery (μg) (μg) bloodstream
    1 minute 182 ± 1  307 63
    5 minutes 160 ± 30 330 68
  • EXAMPLE 7 Delivery of Paclitaxel to Explanted Porcine Arteries from Polyacrylic Acid-Based Coating
  • A 9.8 mg/ml solution of radio-labeled paclitaxel in chloroform is prepared. A total of 50 μl of the solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating. The coated balloon. catheter is then delivered to an explanted porcine artery for 15 minutes. After delivery, the paclitaxel remaining in the coating is extracted using two sequential ethanol washes. The delivered paclitaxel is extracted from the vessel, also by using two sequential ethanol washes. In addition, the vessel is placed in tissue solvent and counted for paclitaxel. Using these extraction methods,. at least 80% of the paclitaxel loaded onto the balloon catheter is recovered, as shown in Table III.
    TABLE III
    Paclitaxel recovery from ex vivo delivery to porcine artery.
    Amount paclitaxel loaded onto balloon 489 μg
    Amount paclitaxel extracted from the 360 μg
    balloon after delivery
    Amount paclitaxel extracted from artery  30 μg
    Amount paclitaxel counted from tissue  1 μg
    solution
    Total paclitaxel measured 391 μg
    Percentage of paclitaxel recovered 80%
  • EXAMPLE 8 Release Kinetics of Paclitaxel from Polyurethane-Based Stent Coating
  • Slotted tube stainless steel stents are coated with polyurethane by spraying a 1 wt% solution of CHRONOFLEX® polyurethane (made by CT Biomaterials) in tetrahydrofuran directly onto the stent surface. The coated stents are dried in a vacuum oven for three hours at 70° C.
  • Each polyurethane coated stent is placed in a vial, which is filled to maximum volume (1.5 ml) with a solution of paclitaxel in ethanol, and sealed. The stent is stored in the vial for three days at room temperature. The stent is then removed from the vial and dried for one hour at 65° C.
  • The above procedure is conducted using solutions of varying concentrations. Each stent is analyzed for paclitaxel content by extraction in dichloromethane. solvent. The results are presented in Table IV below. Samples 1 and 2 were obtained using a paclitaxel concentration of 10 mg/ml, samples 3 and 4 using a 20 mg/ml solution and sample 5 and 6 using a 30 mg/ml solution.
    TABLE IV
    Paclitaxel content.
    μg
    Paclitaxel Paclitaxel Coating Paclitaxel
    conc. content Wt. per
    Sample # (mg/ml) (μg) (μg) μg coating
    1 10 44.8 796 0.06
    2 10 88.2 859 0.10
    3 20 151.2 718 0.21
    4 20 127.6 702 0.18
    5 30 157.1 736 0.21
    6 30 144.3 629 0.23
  • These results suggest that paclitaxel loading is relatively independent of paclitaxel concentration above 20 mg/ml, assuming equilibrium is attained in the three-day period. Nevertheless, the 30 mg/ml paclitaxel concentration is chosen for release studies as it produces the maximum paclitaxel loading (21-23%), while still being sufficiently below the saturation concentration for paclitaxel in ethanol (39 mg/ml).
  • Seven polyurethane coated stents are loaded using a 30 mg/ml paclitaxel solution, removed and dried as set forth above. Paclitaxel from four of the stents is extracted in dichloromethane solvent. The results of this extraction are presented in Table V below:
    TABLE V
    Paclitaxel content.
    Paclitaxel Paclitaxel Coating μg Paclitaxel
    conc. content Wt. per
    Sample # (mg/ml) (μg) (μg) μg coating
    1 30 111.7 676 0.17
    2 30 50 627 0.08
    3 30 45.3 612 0.07
    4 30 37.4 602 0.06
  • The remaining three stents are immersed in a solution of phosphate buffered saline solution having pH 7.4 at 37° C. Cumulative release as a function of time is presented in FIG. 8.
  • EXAMPLE 9 Release Kinetics of Paclitaxel from Polyurethane-Based Balloon Catheter Coating
  • Nylon balloons are coated with polyurethane by dipping into a 9 wt% solution of CHRONOFLEX® polyurethane in dimethylacetamide. The balloons are dried in a vacuum oven overnight at 50° C.
  • Each polyurethane coated balloon is loaded with paclitaxel either by dipping the coated balloon into a paclitaxel and ethanol solution or by dripping a known volume of a paclitaxel and ethanol solution onto the balloon surface.
  • In the first instance, a stock saturated solution of paclitaxel in ethanol is prepared. Then the polyurethane-coated balloon is inflated and submerged in the paclitaxel stock solution in a tube. The tube and balloon are well-sealed to prevent solvent evaporation. After remaining in the tube overnight, the ethanol is evaporated from the balloon over a suitable time period, such as about fifteen minutes. Five “dip-coated” balloons are prepared in this fashion.
  • In the second instance, a stock solution of paclitaxel having a concentration of 10 mg/ml prepared. Twenty ml of this paclitaxel stock solution are then pipetted onto an inflated polyurethane-coated balloon, providing a total mass of 200 mg of paclitaxel per balloon. Afterwards, ethanol is evaporated from the balloon over a suitable time period, such as about fifteen minutes. Five “drip-coated” balloons are prepared in this fashion.
  • Two drip-loaded balloons and two dip-loaded balloons are taken and the paclitaxel extracted in dichloromethane to determine total paclitaxel content. The paclitaxel content of the dip-coated balloons is found to be 1093+/−439 μg, while the drip-coated balloons are found to have 215+/−11 μg paclitaxel.
  • For comparison, nylon balloons are coated with paclitaxel/polyurethane by dipping the balloons into a dispersion of 14.5 wt % BAHYDROL® polyurethane (made by Bayer) and 2.6 wt % paclitaxel in a mixture of 73.6 volt N-methylpyrrolidinone and 26.4 volt water. Balloons are dried in a vacuum oven overnight at 50° C. The dried coatings contain 15% paclitaxel by weight. Nine balloons are formed. Seven balloons are tested for paclitaxel loading yielding an average of 196+/−44 μg paclitaxel after extraction in dichloromethane.
  • The remaining three drip-loaded balloons from above, the remaining three dip-loaded balloons from above, and the remaining two balloons with the 15% paclitaxel formulated coating are placed in a solution of phosphate buffered saline solution having pH 7.4 at 37° C., and cumulative paclitaxel release is measured as a function of time. The results of this study are presented in FIG. 9.
  • EXAMPLE 10 Preparation of a Stent-Coated with a Polylactic Acid/Polycaprolactone (PLA/PCL) Copolymer/Paclitaxel Matrix
  • PLA/PCL copolymer obtained from Birmingham Polymers, Inc., Birmingham, Ala., was dissolved in chloroform. Paclitaxel obtained from Hauser, Inc. was then dissolved in the chloroform to form a solution having a 70/30 weight ratio of copolymer/paclitaxel. The solution was then sprayed onto the surface of a 9 mm long balloon-expandable stainless steel NIR® stent obtained from Medinol, Inc., Tel Aviv, Israel. Substantially all exposed surfaces of the stent were covered with the solution. The stent was then dried in a vacuum oven at 50° C. for approximately 2 hr. and a matrix of PLA/PCL copolymer having 200 μg of paclitaxel incorporated therein was thus formed as a coating on the stent. The paclitaxel component of the matrix comprised approximately 30% by weight of the matrix.
  • EXAMPLE 11 In-vitro Delivery of Paclitaxel to Porcine Coronary Arteries
  • A stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a porcine coronary artery. In vitro, the stent delivered 2-3 μg/day of paclitaxel over a period of 28 days. In comparison to the same stent having no coating, after 28 days, a 50% reduction in the occurrence of neointimal hyperplasia was observed.
  • EXAMPLE 12 In-vitro Delivery of Paclitaxel to Rabbit Iliac
  • A stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a rabbit iliac. In vitro, the stent delivered 2-3 μg/day of paclitaxel over a period of 28 days. In comparison to the same stent having no coating, after 28 days, a 70% reduction in the occurrence of neointimal hyperplasia was observed.
  • EXAMPLE 13 In-vitro Delivery of Paclitaxel to Rabbit Iliac
  • A stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a rabbit iliac. In vitro, the stent delivered 2-3 μg/day of paclitaxel over a period of 56 days. In comparison to the same stent having no coating, after 56 days, a 60% reduction in the occurrence of neointimal hyperplasia was observed.
  • COMPARATIVE EXAMPLE 14 Coil Stents with Biocompatible Polymeric Material/TAXOL® Coating
  • The results presented in Table VI below were obtained by Leon et al., “TAXOL®-Coated Coronary Stents: Potential to Reduce Proliferation,” European Society of Cardiology, Vienna, Austria 1998. GR-II® coil stents, available from Cook Inc., Bloomington, Ind., were coated with a biocompatible polymeric coating incorporating 175-200 μg of TAXOL® and exhibiting in vitro release kinetics of 0.75 μg/day for the first 30 days. The stents were placed in porcine coronary arteries and the effect on neointima formation compared to that seen with control stents was analyzed. The results are shown in Table VI below:
    TABLE VI
    TAXOL ®-Coated Stents versus Control
    TAXOL ®-coated
    Control (N = 10) Stent (N = 9)
    Reference Vessel 2.9 ± 0.3 3.0 ± 0.2
    Diameter (mm)
    Stent/Artery 1.1 ± 0.1 1.1 ± 0.1
    Diameter Stenosis 51 ± 27  27 ± 27*
    (%)
    Neointima Area 669 ± 357  403 ± 197*
    (μm)

    *p < 0.05 versus control
  • In contrast to the results obtained in Example 11 above using the NIR® non-coiled stent in a porcine coronary artery (neointimal hyperplasia reduction of 50%), the results obtained with a coil stent and paclitaxel (placed in a porcine coronary artery) show a neointimal hyperplasia reduction of only 40% calculated as follows: [(669−403)/669]×100=40%.
  • COMPARATIVE EXAMPLE 15 Comparison of Low-dose and High Dose TAXOL®-Coated Stents Versus Control
  • The results of another study by Leon et al., “TAXOL®-Coated Coronary Stents: Potential to Reduce Proliferation,” European Society of Cardiology, Vienna, Austria 1998 on the effect of coated coil stents on neointima formation using 2 doses of “fast-release” TAXOL® are shown in Table VII below: The results for both “low-dose” and “high-dose” TAXOL®-coated stents are shown in Table VII below:
    TABLE VII
    Low-Dose and High Dose TAXOL ®-Coated Stents
    versus Control
    Low-Dose High-Dose
    Control TAXOL ® TAXOL ®
    (N = 12) (N = 10) (N = 11)
    Reference 2.8 ± 0.2 2.8 ± 0.7 3.0 ± 0.3
    Vessel
    Diameter
    (mm)
    Stent/Artery 1.16 ± 0.09 1.15 ± 0.07 1.14 ± 0.05
    Diameter 34.8 ± 15.6  19.3 ± 9.45*  15.1 ± 6.61*†
    Stenosis (%)
    Neointima 1.52 ± 0.78 1.07 ± 0.53  0.93 ± 0.5*†
    Area (μm)

    *p < 0.05 versus control

    †p = not significant versus low-dose TAXOL ®
  • In contrast to the results obtained in Examples 11-13 above using the NIR® non-coiled stent (neointimal hyperplasia reduction of from 50-70%), the above results obtained with a coated coil stent show a neointimal hyperplasia reduction of only 30% and 39%, respectively, calculated as follows: [(1.52−1.07)/1.52]×100=30% (low-dose TAXOL®) and [(1.52−0.93)/1.52)]×100=39% (high-dose TAXOL®).
  • EXAMPLE 16 Preparation of a Vena Cava Filter Coated with a Polylactic Acid/Polycaprolactone(PLA/PCL) Copolymer/Paclitaxel Matrix
  • A filter for placement in the vena cava for capturing blood clots is coated with a PLA/PCL copolymer/paclitaxel matrix in the manner substantially as set forth in Example 10. The filter is sized and constructed to be compressed and passed through the vasculature of a patient to be anchored against an inner wall surface of a blood vessel for capturing blood clots in a blood stream passing therethrough. The filter is described in International Application No. WO 96/17634.
  • EXAMPLE 17 Preparation of a Vena Cava Filter Coated with a Polylactic Acid/Polycaprolactone (PLA/PCL) Copolymer/Paclitaxel Matrix
  • A filter for placement in the vena cava for capturing blood clots is coated with a PLA/PCL copolymer/paclitaxel matrix in the manner substantially as set forth in Example 10. The filter is also adapted for placement in a blood vessel for capturing blood clots in a blood stream passing therethrough. This filter is provided with struts that minimize the risk of vessel damage if the vessel is compressed asymmetrically. The filter is described in International Application No. WO 96/12448.
  • EXAMPLE 18 Preparation of a Vascular Graft Coated with a Polylactic Acid/Polycaprolactone (PLA/PCL) Copolymer/Paclitaxel Matrix
  • A woven synthetic vascular graft for replacement of a segment a blood vessel is coated with a PLA/PCL copolymer/paclitaxel matrix in a manner substantially as set forth in Example 10. The vascular graft is ravel-resistant due to inclusion of a fusible component and self-supporting due to inclusion of a stiffening component. The vascular graft is described in U.S. Pat. No. 5,509,931.
  • It is to be appreciated that the parameters described in the above examples are merely illustrative and. that the present invention is not so limited. For example, in each of the examples provided, any suitable polymer may be used for the polymer coating, any suitable drying time periods and temperatures may be used, any suitable organic solvent may be used, any suitable method for applying the polymer coatings to the medical devices may be used, any suitable method for applying the drugs to the polymer coatings may be used, any suitable water-insoluble analogue of the disclosed drugs may be used, and any suitable drug loading concentrations may be used.
  • The present invention provides a previously unknown method and medical device for the localized delivery of substantially water-insoluble drugs. The present invention provides, in one embodiment, a paclitaxel/polymer coated stent which has an extended release rate of from about 0.2 to about 7 μg per day, Preferably in the range of from about 0.5 to about 5 μg per lay over an extended period of at least about 28 days. In a preferred embodiment of the invention, there is provided a polymer/paclitaxel coated non-coiled stent which has an extended release rate of paclitaxel and which reduces neointima formation in injured blood vessels and other body lumens into which it is placed. The extended release rate is effective to prevent, decrease, eliminate, or modify cellular proliferation associated with neointima formation and/or other proliferative disease or disorder.
  • Those with skill in the art may recognize various modifications to the embodiments of the invention described and illustrated herein. Such modifications are meant to be covered by the spirit and scope of the appended claims.

Claims (29)

1. A catheter for delivering a substantially water-insoluble drug at a desired location within a body, comprising:
a catheter for insertion into a body lumen, having a shaft and an expandable balloon at a distal end of the shaft,
said balloon having a polymer coating on at least a portion of an exterior surface,
said polymer coating having a thickness of between about 0.2 and 50 microns, said polymer coating containing at least one substantially water-insoluble drug.
2. The catheter of claim 1, wherein said polymer coating has a thickness of between about 1 and 10 microns.
3. The catheter of claim 1, wherein said polymer coating has a thickness of between about 2 and 5 microns.
4. The catheter of claim 1, wherein said polymer coating has a thickness of between about 0.2 and 0.3 microns.
5. The catheter of claim 1, wherein said polymer coating has a thickness greater than about 10 microns.
6. The catheter of claim 1, wherein said polymer coating is layered.
7. The catheter of claim 1, wherein said polymer is hydrophillic.
8. The catheter of claim 1, wherein said polymer is hydrophobic.
9. The catheter of claim 1, wherein said polymer is a polyvinyl aromatic.
10. The catheter of claim 1, wherein said at least one substantially water-insoluble drug is paclitaxel.
11. The catheter of claim 1, wherein said at least one water-insoluble drug comprises a combination of paclitaxel and an agent selected from the group consisting of anti-coagulants, anti-mitotics, anti-thrombogenics, thrombolytics, anti-inflammatory agents, nitric oxide containing polymers, or vascular cell promoters.
12. The catheter of claim 1, wherein said at least one water-insoluble drug is released from said stent over a time frame effective to inhibit proliferative disease when said catheter is positioned at a site of injury to thereby prevent or inhibit undesired cellular proliferation.
13. A method of preparing a balloon catheter having a balloon with a substantially water-insoluble drug coating comprising:
dissolving at least one substantially water-insoluble drug in an organic solvent to create a drug solution; and
applying said drug solution to at least a portion of an exterior surface of the balloon.
14. The method of claim 13, further comprising the step of coating at least a portion of the exterior surface of said balloon with a polymer to form a polymer coating prior to applying said drug solution to at least a portion of the exterior surface of said balloon.
15. The method of claim 14, further comprising the step of evaporating said organic solvent from said polymer coating after applying said drug solution.
16. The method of claim 15, wherein the step of evaporating the organic solvent from said polymer coating is performed in a vacuum oven.
17. The method of claim 13, wherein said drug solution is applied by dipping, dripping, spraying, or pipeting.
18. The method of claim 15, further comprising the step of applying an additional modifying or modulating layer after evaporating said organic solvent.
19. The method of claim 18, wherein said additional modifying or modulating layer comprises a polymer.
20. The method of claim 18, wherein said additional modifying or modulating layer comprises a drug.
21. The method of claim 18, wherein the additional modifying or modulating layer has a thickness of less than about 5000 angstroms.
22. The method of claim 18, wherein the additional modifying or modulating layer has a thickness of between about 50 and 2000 angstroms.
23. The method of claim 14, wherein said polymer coating has a thickness of between about 1 and 10 microns.
24. The method of claim 14, wherein said polymer coating has a thickness of between about 2 and 5 microns.
25. The method of claim 13, wherein the organic solvent is chosen from the group consisting of: ethanol, isopropanol, chloroform, acetone, pentane, hexane, and methylene chloride.
26. The method of claim 13, wherein the organic solvent is chloroform.
27. The method of claim 13, wherein said at least one substantially water-insoluble drug is paclitaxel.
28. The method of claim 13, wherein said at least one water-insoluble drug comprises a combination of paclitaxel and an agent selected from the group consisting of anti-coagulants, anti-mitotics, anti-thrombogenics, thrombolytics, anti-inflammatory agents, nitric oxide containing polymers, or vascular cell promoters.
29. A method of preparing a balloon catheter having a balloon with a substantially water-insoluble drug coating, comprising:
a catheter for insertion into a body lumen, having a shaft and an expandable balloon at a distal end of the shaft,
said balloon having a polymer coating on at least a portion of an exterior surface,
said polymer coating having a thickness of between about 0.2 and 50 microns,
said polymer coating containing at least one substantially water-insoluble drug, said method comprising the steps of:
dissolving said at least one substantially water-insoluble drug in an organic solvent to create a drug solution; and
applying said drug solution to at least a portion of the exterior surface of said balloon.
US11/833,717 1997-08-13 2007-08-03 Loading and release of water-insoluble drugs Abandoned US20080021385A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US91013697A true 1997-08-13 1997-08-13
US13360398A true 1998-08-13 1998-08-13
US09/172,026 US6306166B1 (en) 1997-08-13 1998-10-14 Loading and release of water-insoluble drugs
US09/978,763 US20020037358A1 (en) 1997-08-13 2001-10-18 Loading and release of water-insoluble drugs
US11/188,850 US20060002973A1 (en) 1997-08-13 2005-07-26 Loading and release of water-insoluble drugs
US11/833,717 US20080021385A1 (en) 1997-08-13 2007-08-03 Loading and release of water-insoluble drugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/833,717 US20080021385A1 (en) 1997-08-13 2007-08-03 Loading and release of water-insoluble drugs
US13/085,623 US20110196340A1 (en) 1997-08-13 2011-04-13 Loading and release of water-insoluble drugs
US13/483,850 US20120239001A1 (en) 1997-08-13 2012-05-30 Loading and release of water-insoluble drugs
US13/888,954 US20130304029A1 (en) 1997-08-13 2013-05-07 Loading and release of water-insoluble drugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/188,850 Division US20060002973A1 (en) 1997-08-13 2005-07-26 Loading and release of water-insoluble drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/085,623 Division US20110196340A1 (en) 1997-08-13 2011-04-13 Loading and release of water-insoluble drugs

Publications (1)

Publication Number Publication Date
US20080021385A1 true US20080021385A1 (en) 2008-01-24

Family

ID=22626067

Family Applications (7)

Application Number Title Priority Date Filing Date
US09/172,026 Expired - Fee Related US6306166B1 (en) 1997-08-13 1998-10-14 Loading and release of water-insoluble drugs
US09/978,763 Abandoned US20020037358A1 (en) 1997-08-13 2001-10-18 Loading and release of water-insoluble drugs
US11/188,850 Abandoned US20060002973A1 (en) 1997-08-13 2005-07-26 Loading and release of water-insoluble drugs
US11/833,717 Abandoned US20080021385A1 (en) 1997-08-13 2007-08-03 Loading and release of water-insoluble drugs
US13/085,623 Abandoned US20110196340A1 (en) 1997-08-13 2011-04-13 Loading and release of water-insoluble drugs
US13/483,850 Abandoned US20120239001A1 (en) 1997-08-13 2012-05-30 Loading and release of water-insoluble drugs
US13/888,954 Abandoned US20130304029A1 (en) 1997-08-13 2013-05-07 Loading and release of water-insoluble drugs

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/172,026 Expired - Fee Related US6306166B1 (en) 1997-08-13 1998-10-14 Loading and release of water-insoluble drugs
US09/978,763 Abandoned US20020037358A1 (en) 1997-08-13 2001-10-18 Loading and release of water-insoluble drugs
US11/188,850 Abandoned US20060002973A1 (en) 1997-08-13 2005-07-26 Loading and release of water-insoluble drugs

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/085,623 Abandoned US20110196340A1 (en) 1997-08-13 2011-04-13 Loading and release of water-insoluble drugs
US13/483,850 Abandoned US20120239001A1 (en) 1997-08-13 2012-05-30 Loading and release of water-insoluble drugs
US13/888,954 Abandoned US20130304029A1 (en) 1997-08-13 2013-05-07 Loading and release of water-insoluble drugs

Country Status (6)

Country Link
US (7) US6306166B1 (en)
EP (2) EP1800702A3 (en)
AT (1) AT357265T (en)
AU (1) AU1108800A (en)
DE (1) DE69935605T2 (en)
WO (1) WO2000021584A1 (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118544A1 (en) * 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices
US20080255509A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080255508A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) * 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20090227948A1 (en) * 2008-03-06 2009-09-10 Boston Scientific Scimed, Inc. Balloon catheter devices with sheath covering
US20100063585A1 (en) * 2006-07-03 2010-03-11 Hemoteq Ag Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open
US20100068170A1 (en) * 2008-09-15 2010-03-18 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100076401A1 (en) * 2008-09-25 2010-03-25 Randolf Von Oepen Expandable Member Having A Covering Formed Of A Fibrous Matrix For Intraluminal Drug Delivery
US20100081992A1 (en) * 2008-09-26 2010-04-01 Ehrenreich Kevin J Expandable Member Formed Of A Fibrous Matrix For Intraluminal Drug Delivery
US20100179475A1 (en) * 2007-01-21 2010-07-15 Erika Hoffmann Medical product for treating stenosis of body passages and for preventing threatening restenosis
US20100209472A1 (en) * 2006-11-20 2010-08-19 Lixiao Wang Drug releasing coatings for medical devices
WO2010108678A1 (en) * 2009-03-25 2010-09-30 Karl-Heinz Marx Kit for providing an artificial stomach entrance
US20100285085A1 (en) * 2009-05-07 2010-11-11 Abbott Cardiovascular Systems Inc. Balloon coating with drug transfer control via coating thickness
US20110021985A1 (en) * 2007-05-14 2011-01-27 Konstantinos Spargias Anti-restenosis drug covered and eluting balloons for valvuloplasty of aortic valve stenosis for the prevention of restenosis
US20110092900A1 (en) * 2008-04-09 2011-04-21 Alexander Rubben Method for Producing a Bioactive Surface on an Endoprosthesis or on the Balloon of a Balloon Catheter
US20110098737A1 (en) * 2007-04-13 2011-04-28 Konstantinos Spargias Anti-restenosis drug covered and eluting balloons for valvuloplasty of aortic valve stenosis for the prevention of restenosis
US20110160698A1 (en) * 2007-07-03 2011-06-30 Hemoteq Ag Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis
US20110238011A1 (en) * 2007-08-03 2011-09-29 Bruno Scheller pharmaceutical-coated medical products, the production thereof and the use thereof
US8049061B2 (en) 2008-09-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
US20110306825A1 (en) * 2010-06-10 2011-12-15 Myriad Medical LLC Intracavity balloon catheter
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8177743B2 (en) 1998-05-18 2012-05-15 Boston Scientific Scimed, Inc. Localized delivery of drug agents
WO2012072074A1 (en) * 2010-12-04 2012-06-07 Ruebben Alexander Coating and coating method for the balloon of a balloon catheter, and balloon catheter with coated balloon
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
WO2013015941A1 (en) 2011-07-26 2013-01-31 Medtronic Vascular Inc. Textured dilatation balloon
US8500687B2 (en) 2008-09-25 2013-08-06 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9011896B2 (en) 2010-04-19 2015-04-21 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9180485B2 (en) 2008-08-29 2015-11-10 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9415193B2 (en) 2011-03-04 2016-08-16 W. L. Gore & Associates, Inc. Eluting medical devices
US9586031B2 (en) 2005-05-11 2017-03-07 Angioscore, Inc. Methods and systems for delivering substances into luminal walls
US9592322B2 (en) 2012-03-27 2017-03-14 Terumo Kabushiki Kaisha Coating composition and medical device
US9603974B2 (en) 2012-03-27 2017-03-28 Terumo Kabushiki Kaisha Coating composition and medical device
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9901715B2 (en) 2012-09-05 2018-02-27 W. L. Gore Associates, Inc. Retractable sheath devices, systems, and methods
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US10179249B2 (en) 2015-01-08 2019-01-15 Myriad Medical, Llc Intracavity balloon catheter
US10195311B2 (en) 2009-12-18 2019-02-05 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7896914B2 (en) 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7867275B2 (en) 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US7550005B2 (en) 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20030093143A1 (en) * 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20070093889A1 (en) * 1999-01-27 2007-04-26 Wu Benjamin M Non-Fragmenting Low Friction Bioactive Absorbable Coils for Brain Aneurysm Therapy
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US8303609B2 (en) 2000-09-29 2012-11-06 Cordis Corporation Coated medical devices
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
WO2000010622A1 (en) * 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US20050171594A1 (en) * 1998-12-31 2005-08-04 Angiotech International Ag Stent grafts with bioactive coatings
US20020065546A1 (en) * 1998-12-31 2002-05-30 Machan Lindsay S. Stent grafts with bioactive coatings
US6709465B2 (en) 1999-03-18 2004-03-23 Fossa Medical, Inc. Radially expanding ureteral device
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
WO2001087491A1 (en) 2000-05-16 2001-11-22 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US6974473B2 (en) * 2000-06-30 2005-12-13 Vascular Architects, Inc. Function-enhanced thrombolytic AV fistula and method
US6620196B1 (en) * 2000-08-30 2003-09-16 Sdgi Holdings, Inc. Intervertebral disc nucleus implants and methods
EP1992317B1 (en) 2000-08-30 2012-02-29 Johns Hopkins University Devices for intraocular drug delivery
WO2002032347A2 (en) 2000-10-16 2002-04-25 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6607553B1 (en) 2000-11-17 2003-08-19 B. Braun Medical, Inc. Method for deploying a thermo-mechanically expandable stent
PL362249A1 (en) * 2000-12-04 2004-10-18 Grüssner Uwe Emil Method for producing a partial or complete active ingredient coating on and in implants and onplants
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
DE10115740A1 (en) * 2001-03-26 2002-10-02 Ulrich Speck Preparation for the prophylaxis of restenosis
US7622146B2 (en) * 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US6656216B1 (en) * 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
WO2003020331A1 (en) * 2001-09-03 2003-03-13 Oxigene, Inc. Implants containing combretastatin a-4
US8303651B1 (en) 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
GB0121980D0 (en) * 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
AU2007202976B2 (en) * 2001-09-24 2008-12-04 Boston Scientific Limited Optimized dosing for drug coated stents
US20050025808A1 (en) * 2001-09-24 2005-02-03 Herrmann Robert A. Medical devices and methods for inhibiting smooth muscle cell proliferation
JP4393870B2 (en) * 2001-09-24 2010-01-06 ボストン サイエンティフィック リミテッド Optimal dose for drug-coated stents
AU2002328729C1 (en) * 2001-10-01 2009-11-26 Matrizyme Pharma Corporation Use of collagenase to facilitate guide wire crossing in total arterial occlusions
US20030065382A1 (en) * 2001-10-02 2003-04-03 Fischell Robert E. Means and method for the treatment of coronary artery obstructions
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US20040111108A1 (en) * 2001-11-09 2004-06-10 Farnan Robert C. Balloon catheter with non-deployable stent
CN100502806C (en) 2001-11-09 2009-06-24 诺沃斯特公司 Balloon catheter with non-deployable stent
CA2467239A1 (en) * 2001-11-14 2003-05-22 Alza Corporation Catheter injectable depot compositions and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US8080048B2 (en) 2001-12-03 2011-12-20 Xtent, Inc. Stent delivery for bifurcated vessels
US7294146B2 (en) 2001-12-03 2007-11-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US7182779B2 (en) * 2001-12-03 2007-02-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US7270668B2 (en) * 2001-12-03 2007-09-18 Xtent, Inc. Apparatus and methods for delivering coiled prostheses
US7351255B2 (en) * 2001-12-03 2008-04-01 Xtent, Inc. Stent delivery apparatus and method
US7892273B2 (en) * 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US7309350B2 (en) * 2001-12-03 2007-12-18 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US20030135266A1 (en) * 2001-12-03 2003-07-17 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7147656B2 (en) * 2001-12-03 2006-12-12 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7364586B2 (en) * 2001-12-21 2008-04-29 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
US8142412B2 (en) * 2002-01-03 2012-03-27 Oxira Medical Inc. Method and apparatus for delivering oxygen and/or other gases to tissue
US7709048B2 (en) * 2002-05-02 2010-05-04 Labcoat, Ltd. Method and apparatus for coating a medical device
US7048962B2 (en) * 2002-05-02 2006-05-23 Labcoat, Ltd. Stent coating device
US6645547B1 (en) * 2002-05-02 2003-11-11 Labcoat Ltd. Stent coating device
US20030208166A1 (en) * 2002-05-06 2003-11-06 Schwartz Anthony H. Implantable device with free-flowing exit and uses thereof
AU2003243885B8 (en) * 2002-05-09 2009-08-06 Hemoteq Ag Medical products comprising a haemocompatible coating, production and use thereof
DE10261986B4 (en) * 2002-05-10 2008-01-31 Hemoteq Ag Hemocompatibly coated surfaces, to processes for their preparation and their uses
ES2369640T3 (en) * 2002-05-24 2011-12-02 Angiotech International Ag Compositions and methods for coating medical implants.
US7939094B2 (en) 2002-06-19 2011-05-10 Boston Scientific Scimed, Inc. Multiphase polymeric drug release region
US7105175B2 (en) * 2002-06-19 2006-09-12 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US8211455B2 (en) * 2002-06-19 2012-07-03 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AT495769T (en) 2002-07-12 2011-02-15 Cook Inc Coated medical device
US8501215B2 (en) * 2002-07-31 2013-08-06 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
EP1526835B1 (en) * 2002-07-31 2008-04-23 ALZA Corporation Injectable depot compositions and uses thereof
US20040024448A1 (en) * 2002-08-05 2004-02-05 Chang James W. Thermoplastic fluoropolymer-coated medical devices
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck A medical device for drug delivery
EP1628597A4 (en) * 2003-05-28 2008-12-10 Conor Medsystems Inc Methods of delivering anti-restenotic agents from a stent
US7758636B2 (en) 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
JP2006516202A (en) * 2002-12-30 2006-06-29 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Silk stent graft
US20040186551A1 (en) * 2003-01-17 2004-09-23 Xtent, Inc. Multiple independent nested stent structures and methods for their preparation and deployment
US8080026B2 (en) 2003-01-21 2011-12-20 Angioscore, Inc. Apparatus and methods for treating hardened vascular lesions
US8313759B2 (en) * 2003-03-06 2012-11-20 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing miscible polymer blends for controlled delivery of a therapeutic agent
US7445792B2 (en) 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
WO2004087214A1 (en) 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device with beneficial agent concentration gradient
US7241308B2 (en) * 2003-06-09 2007-07-10 Xtent, Inc. Stent deployment systems and methods
US7318945B2 (en) * 2003-07-09 2008-01-15 Medtronic Vascular, Inc. Laminated drug-polymer coated stent having dipped layers
US7335185B2 (en) * 2003-07-18 2008-02-26 Boston Scientific Scimed, Inc. Protective coatings for medical devices
US6840569B1 (en) * 2003-07-22 2005-01-11 Arthur Donald Leigh Caravan
US7744645B2 (en) * 2003-09-29 2010-06-29 Medtronic Vascular, Inc. Laminated drug-polymer coated stent with dipped and cured layers
US20050080475A1 (en) * 2003-10-14 2005-04-14 Xtent, Inc. A Delaware Corporation Stent delivery devices and methods
US7553324B2 (en) * 2003-10-14 2009-06-30 Xtent, Inc. Fixed stent delivery devices and methods
US7192440B2 (en) * 2003-10-15 2007-03-20 Xtent, Inc. Implantable stent delivery devices and methods
US7553326B2 (en) * 2003-11-24 2009-06-30 Sweet Richard M Method and apparatus for preventing dialysis graft intimal hyperplasia
US7403966B2 (en) * 2003-12-08 2008-07-22 Freescale Semiconductor, Inc. Hardware for performing an arithmetic function
US20070156225A1 (en) * 2003-12-23 2007-07-05 Xtent, Inc. Automated control mechanisms and methods for custom length stent apparatus
US7326236B2 (en) * 2003-12-23 2008-02-05 Xtent, Inc. Devices and methods for controlling and indicating the length of an interventional element
US8309112B2 (en) * 2003-12-24 2012-11-13 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same
DE102004009318B4 (en) * 2004-02-26 2006-05-04 Siemens Ag Apparatus for repeated semi-invasive abrasion changes on the walls of hollow organs
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
AT534424T (en) * 2004-03-19 2011-12-15 Abbott Lab Multiple drug delivery of a balloon and a prosthesis
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US7323006B2 (en) * 2004-03-30 2008-01-29 Xtent, Inc. Rapid exchange interventional devices and methods
US20050226991A1 (en) * 2004-04-07 2005-10-13 Hossainy Syed F Methods for modifying balloon of a catheter assembly
US20050228477A1 (en) * 2004-04-09 2005-10-13 Xtent, Inc. Topographic coatings and coating methods for medical devices
JP2007534389A (en) * 2004-04-29 2007-11-29 キューブ・メディカル・アクティーゼルスカブCube Medical A/S Balloon used in angioplasty
US20050255230A1 (en) * 2004-05-17 2005-11-17 Clerc Claude O Method of manufacturing a covered stent
AT423578T (en) * 2004-05-27 2009-03-15 Medtronic Inc Medical product with a biological active substance-
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US20050288766A1 (en) * 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US8236338B2 (en) 2004-07-13 2012-08-07 The University Of Tennessee Research Foundation Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts
EP1791496A4 (en) 2004-08-31 2013-05-29 Bard Inc C R Self-sealing ptfe graft with kink resistance
CA2610896C (en) 2005-06-17 2014-07-08 C.R. Bard, Inc. Vascular graft with kink resistance after clamping
US20060069424A1 (en) * 2004-09-27 2006-03-30 Xtent, Inc. Self-constrained segmented stents and methods for their deployment
US9011831B2 (en) * 2004-09-30 2015-04-21 Advanced Cardiovascular Systems, Inc. Methacrylate copolymers for medical devices
US20060093643A1 (en) * 2004-11-04 2006-05-04 Stenzel Eric B Medical device for delivering therapeutic agents over different time periods
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060206139A1 (en) * 2005-01-19 2006-09-14 Tekulve Kurt J Vascular occlusion device
US7402168B2 (en) * 2005-04-11 2008-07-22 Xtent, Inc. Custom-length stent delivery system with independently operable expansion elements
JP2008543376A (en) * 2005-06-08 2008-12-04 シー・アール・バード・インコーポレーテッドC R Bard Incorporated Graft and stent having an inorganic biocompatible calcium salts
US9101949B2 (en) 2005-08-04 2015-08-11 Eilaz Babaev Ultrasonic atomization and/or seperation system
US7896539B2 (en) 2005-08-16 2011-03-01 Bacoustics, Llc Ultrasound apparatus and methods for mixing liquids and coating stents
US20100268321A1 (en) * 2005-09-06 2010-10-21 C R Bard, Inc. Drug-releasing graft
AU2006304229A1 (en) 2005-10-13 2007-04-26 Synthes Gmbh Drug-impregnated encasement
WO2007056761A2 (en) 2005-11-09 2007-05-18 C.R. Bard Inc. Grafts and stent grafts having a radiopaque marker
CN1962155A (en) * 2005-11-10 2007-05-16 鸿富锦精密工业(深圳)有限公司 CO2 laser welding apparatus
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US8092819B2 (en) * 2006-01-27 2012-01-10 Cook Medical Technologies LLC. Implantable medical device coated with a bioactive agent
US20070179587A1 (en) * 2006-01-30 2007-08-02 Xtent, Inc. Apparatus and methods for deployment of custom-length prostheses
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) * 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
CA2641117C (en) * 2006-01-31 2018-01-02 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
EP1998716A4 (en) 2006-03-20 2010-01-20 Xtent Inc Apparatus and methods for deployment of linked prosthetic segments
US20070281117A1 (en) * 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
US8703167B2 (en) * 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US20080051702A1 (en) * 2006-08-24 2008-02-28 Herrmann Robert A Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices
US8394488B2 (en) 2006-10-06 2013-03-12 Cordis Corporation Bioabsorbable device having composite structure for accelerating degradation
US9198749B2 (en) 2006-10-12 2015-12-01 C. R. Bard, Inc. Vascular grafts with multiple channels and methods for making
US9040816B2 (en) * 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
US20080152784A1 (en) * 2006-12-22 2008-06-26 Boston Scientific Scimed, Inc. Methods of manufacturing coatings and coated medical devices
DE102007003184A1 (en) * 2007-01-22 2008-07-24 Orlowski, Michael, Dr. A method for loading of structured surfaces
US20080199510A1 (en) 2007-02-20 2008-08-21 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus
DE102007040868A1 (en) * 2007-08-29 2009-04-16 Innora Gmbh Balloon catheter with protection against unfolding
US20090076584A1 (en) * 2007-09-19 2009-03-19 Xtent, Inc. Apparatus and methods for deployment of multiple custom-length prostheses
CA2715269C (en) * 2008-02-22 2016-09-13 Angiotech International Ag Anti-infective catheters
US9101503B2 (en) * 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
WO2009135125A2 (en) 2008-05-01 2009-11-05 Bayer Schering Pharma Ag Catheter balloon drug adherence techniques and methods
DE102008034826A1 (en) * 2008-07-22 2010-01-28 Alexander Rübben A method for producing a bioactive surface on the balloon of a balloon catheter
US8808347B2 (en) 2008-09-25 2014-08-19 Advanced Bifurcation Systems, Inc. Stent alignment during treatment of a bifurcation
CA2739007C (en) 2008-09-25 2017-10-31 Advanced Bifurcation Systems, Inc. Partially crimped stent
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
US8828071B2 (en) 2008-09-25 2014-09-09 Advanced Bifurcation Systems, Inc. Methods and systems for ostial stenting of a bifurcation
EP3064230B1 (en) 2009-07-10 2019-04-10 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
EP2338534A2 (en) * 2009-12-21 2011-06-29 Biotronik VI Patent AG Medical implant, coating method and implantation method
WO2011081712A1 (en) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
EP2549952A4 (en) 2010-03-24 2017-01-04 Advanced Bifurcation Systems, Inc. System and methods for treating a bifurcation
EP2549958A4 (en) 2010-03-24 2016-09-14 Advanced Bifurcation Systems Inc Methods and systems for treating a bifurcation with provisional side branch stenting
EP2380605A1 (en) 2010-04-19 2011-10-26 InnoRa Gmbh Improved formulations for drug-coated medical devices
EP2383000A1 (en) 2010-04-19 2011-11-02 InnoRa Gmbh Limus-coated medical devices
US8632559B2 (en) 2010-09-21 2014-01-21 Angioscore, Inc. Method and system for treating valve stenosis
WO2012039884A1 (en) 2010-09-23 2012-03-29 Boston Scientific Scimed, Inc. Drug coated balloon with transferable coating
WO2012084024A1 (en) 2010-12-21 2012-06-28 Invatec Technology Center Gmbh Drug eluting balloon for the treatment of stenosis and method for manufacturing the balloon
CA2826760A1 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
WO2012109365A1 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. System and methods for treating a bifurcation with a fully crimped stent
EP2766062B1 (en) 2011-10-14 2015-08-26 Innora GmbH Improved formulations for drug-coated medical devices
WO2013091722A1 (en) 2011-12-23 2013-06-27 Innora Gmbh Drug-coated medical devices
TWI590843B (en) 2011-12-28 2017-07-11 Synthes Gmbh Films and methods of manufacture
US9220584B2 (en) 2012-03-30 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a stent and locally administered adjunctive therapy
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US10117668B2 (en) 2013-10-08 2018-11-06 The Spectranetics Corporation Balloon catheter with non-deployable stent having improved stability
JP6008213B2 (en) * 2014-08-06 2016-10-19 リューベン,アレクサンダー Manufacturing method of the endoprosthesis or on the balloon the balloon on the bioactive surface of the catheter
CN107865982A (en) * 2016-09-28 2018-04-03 先健科技(深圳)有限公司 Medicine coating saccule

Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US556922A (en) * 1896-03-24 gilpatrick
US4026296A (en) * 1974-03-19 1977-05-31 Ceskoslovenska Akademie Ved Hydrophilic surgical tubular device
US4186745A (en) * 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
US4515593A (en) * 1981-12-31 1985-05-07 C. R. Bard, Inc. Medical tubing having exterior hydrophilic coating for microbiocide absorption therein and method for using same
US4589873A (en) * 1984-05-29 1986-05-20 Becton, Dickinson And Company Method of applying a hydrophilic coating to a polymeric substrate and articles prepared thereby
US4644936A (en) * 1982-11-19 1987-02-24 Iabp Percutaneous intra-aortic balloon and method for using same
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4796629A (en) * 1987-06-03 1989-01-10 Joseph Grayzel Stiffened dilation balloon catheter device
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US5087244A (en) * 1989-01-31 1992-02-11 C. R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US5091205A (en) * 1989-01-17 1992-02-25 Union Carbide Chemicals & Plastics Technology Corporation Hydrophilic lubricious coatings
US5102402A (en) * 1991-01-04 1992-04-07 Medtronic, Inc. Releasable coatings on balloon catheters
US5302634A (en) * 1992-10-15 1994-04-12 Hoppmann Corporation Cured unsaturated polyester-polyurethane hybrid highly filled resin foams
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5385152A (en) * 1990-11-09 1995-01-31 Boston Scientific Corporation Guidewire for crossing occlusions in blood vessels
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5609329A (en) * 1994-06-23 1997-03-11 Itt Automotive Europe Gmbh Vibration damping attachment of a drive unit for windshield wipers
US5616149A (en) * 1990-07-03 1997-04-01 Cedars-Sinai Medical Center Balloon catheter with cutting edge
US5624411A (en) * 1993-04-26 1997-04-29 Medtronic, Inc. Intravascular stent and method
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5733925A (en) * 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US6048515A (en) * 1994-08-04 2000-04-11 Institut Fur Diagnostikforschung Gmbh Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US6183658B1 (en) * 1996-04-10 2001-02-06 Institut Für Neue Materialien Gem. Gmbh Process for preparing agglomerate-free nanoscalar iron oxide particles with a hydrolysis resistant coating
US6186745B1 (en) * 1999-04-28 2001-02-13 Chemand Corporation Gas pressurized liquid pump with intermediate chamber
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US20020010489A1 (en) * 2000-07-24 2002-01-24 Jeffrey Grayzel Stiffened balloon catheter for dilatation and stenting
US6355029B1 (en) * 1997-12-02 2002-03-12 Cryovascular Systems, Inc. Apparatus and method for cryogenic inhibition of hyperplasia
US6514245B1 (en) * 1999-03-15 2003-02-04 Cryovascular Systems, Inc. Safety cryotherapy catheter
US6541039B1 (en) * 1997-06-20 2003-04-01 Institut Für Neue Materialien Gem. Gmbh Nanoscale particles having an iron oxide-containing core enveloped by at least two shells
US6548569B1 (en) * 1999-03-25 2003-04-15 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US20040023851A1 (en) * 2000-06-29 2004-02-05 Wolfgang Barnikol Method for the porduction of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross- linking in the presence of chemically non- reacting effectors of the oxygen affinity of the haemoglobin
US6730105B2 (en) * 1988-07-29 2004-05-04 Samuel Shiber Clover leaf shaped tubular medical device
US20040098108A1 (en) * 2002-11-13 2004-05-20 Biotronik Gmbh & Co. Kg Endoprosthesis
US20060013854A1 (en) * 2004-07-19 2006-01-19 Strickler Frederick H Medical devices containing copolymers with graft copolymer endblocks for drug delivery
US20060013853A1 (en) * 2004-07-19 2006-01-19 Richard Robert E Medical devices having conductive substrate and covalently bonded coating layer
US20060020331A1 (en) * 2002-07-12 2006-01-26 Cook Incorporated Coated medical device
US20060025848A1 (en) * 2004-07-29 2006-02-02 Jan Weber Medical device having a coating layer with structural elements therein and method of making the same
US6995661B2 (en) * 2003-07-01 2006-02-07 Nissan Motor Co., Ltd. Vehicular display device
US7005414B2 (en) * 2000-06-29 2006-02-28 Sanguibiotech Gmbh Synthetic oxygen transport made from cross-linked modified human or porcine haemoglobin with improved properties, method for a preparation thereof from purified material and use thereof
US20060057208A1 (en) * 2004-09-16 2006-03-16 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
US20060058815A1 (en) * 2004-09-16 2006-03-16 Mickley Timothy J Expandable multi-port therapeutic delivery system, device, and method
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US20060079836A1 (en) * 2004-10-12 2006-04-13 Holman Thomas J Reinforced and drug-eluting balloon catheters and methods for making same
US20060085058A1 (en) * 2004-10-20 2006-04-20 Rosenthal Arthur L System and method for delivering a biologically active material to a body lumen
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US20070003599A1 (en) * 2002-06-19 2007-01-04 Schwarz Marlene C Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US7160317B2 (en) * 2002-01-04 2007-01-09 Boston Scientific Scimed, Inc. Multiple-wing balloon catheter to reduce damage to coated expandable medical implants
US20070020307A1 (en) * 2005-07-19 2007-01-25 Sheng-Ping Zhong Medical devices containing radiation resistant polymers
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US20070067882A1 (en) * 2005-09-21 2007-03-22 Liliana Atanasoska Internal medical devices having polyelectrolyte-containing extruded regions
US20070083149A1 (en) * 1999-12-30 2007-04-12 Advanced Cardiovascular Systems, Inc. Medical assembly with transducer for local delivery of a therapeutic substance and method of using same
US20070106250A1 (en) * 2002-01-22 2007-05-10 Mercator Medsystems Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US20070112330A1 (en) * 2001-01-17 2007-05-17 Maria Palasis Therapeutic delivery balloon
US20080027421A1 (en) * 2006-07-27 2008-01-31 Vancelette David W CryoBalloon Treatment for Postpartum Hemorrhage
US20080050415A1 (en) * 2006-08-25 2008-02-28 Boston Scientic Scimed, Inc. Polymeric/ceramic composite materials for use in medical devices
US20080051541A1 (en) * 2006-08-25 2008-02-28 Boston Scientific Scimed, Inc. Medical devices having improved mechanical performance
US20080057102A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
US20080095847A1 (en) * 2006-10-18 2008-04-24 Thierry Glauser Stimulus-release carrier, methods of manufacture and methods of treatment
US20080113081A1 (en) * 2004-04-07 2008-05-15 Abbott Cardiovascular Systems Inc. Methods for Modifying Balloon of a Catheter Assembly
US20080118544A1 (en) * 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices
US20090005849A1 (en) * 2006-03-24 2009-01-01 Syed Faiyaz Ahmed Hossainy Methods and apparatuses for coating a lesion
US20090018501A1 (en) * 2007-07-13 2009-01-15 Yribarren Travis R Drug Coated Balloon Catheter
US20090024200A1 (en) * 2007-07-20 2009-01-22 Medtronic Vascular, Inc. Drug Eluting Medical Device and Method
US20090047414A1 (en) * 2004-09-28 2009-02-19 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20090054837A1 (en) * 2006-02-09 2009-02-26 B. Braun Melsungen Ag Coating Method for a Folded Balloon
US20090069883A1 (en) * 1998-04-14 2009-03-12 Ni Ding Medical device with sponge coating for controlled drug release
US20090076448A1 (en) * 2007-09-17 2009-03-19 Consigny Paul M Methods and devices for eluting agents to a vessel
US20090088735A1 (en) * 2004-03-23 2009-04-02 Cryocath Technologies Inc. Method and apparatus for inflating and deflating balloon catheters
US20090105687A1 (en) * 2007-10-05 2009-04-23 Angioscore, Inc. Scoring catheter with drug delivery membrane
US20090105686A1 (en) * 2007-06-29 2009-04-23 Xtent, Inc. Adjustable-length drug delivery balloon
US20090112239A1 (en) * 2007-10-31 2009-04-30 Specialized Vascular Technologies, Inc. Sticky dilatation balloon and methods of using
US20090111960A1 (en) * 2007-10-25 2009-04-30 Boston Scientific Scimed, Inc. Dehydrofluorination and Surface Modification of Fluoropoymers for Drug Delivery Applications
US20100010470A1 (en) * 2008-07-11 2010-01-14 Paragon Intellectual Properties, Llc Nanotube-Reinforced Balloons For Delivering Therapeutic Agents Within Or Beyond The Wall of Blood Vessels, And Methods Of Making And Using Same
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US20100023108A1 (en) * 2004-03-19 2010-01-28 Toner John L Multiple Drug Delivery From A Balloon And A Prosthesis
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20100049294A1 (en) * 2008-06-04 2010-02-25 Zukowski Stanislaw L Controlled deployable medical device and method of making the same
US20100056985A1 (en) * 2008-08-27 2010-03-04 Boston Scientific Scimed, Inc. Electroactive polymer activation system for a medical device
US20100055294A1 (en) * 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100063585A1 (en) * 2006-07-03 2010-03-11 Hemoteq Ag Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20100076542A1 (en) * 2007-02-21 2010-03-25 Eurocor Gmbh Coated expandable system
US20100074934A1 (en) * 2006-12-13 2010-03-25 Hunter William L Medical implants with a combination of compounds
US20100087783A1 (en) * 2008-10-07 2010-04-08 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents to body lumens
US20100092540A1 (en) * 2000-12-12 2010-04-15 Boston Scientific Scimed, Inc. Drug delivery compositions and medical devices containing block copolymer
US20100096781A1 (en) * 2006-01-31 2010-04-22 Abbott Cardiovascular Systems Inc. Method Of Fabricating An Implantable Medical Device Using Gel Extrusion And Charge Induced Orientation
US20100125239A1 (en) * 2008-11-14 2010-05-20 Minnow Medical, Inc. Selective Drug Delivery In a Lumen
US20110054443A1 (en) * 2009-08-31 2011-03-03 Boston Scientific Scimed, Inc. Balloon catheter devices with drug delivery extensions
US20110054396A1 (en) * 2009-08-27 2011-03-03 Boston Scientific Scimed, Inc. Balloon Catheter Devices With Drug-Coated Sheath

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US304121A (en) * 1884-08-26 Helm munch
US4481323A (en) 1980-05-07 1984-11-06 Medical Research Associates, Ltd. #2 Hydrocarbon block copolymer with dispersed polysiloxane
CA1191064A (en) 1981-12-31 1985-07-30 Bard (C. R.), Inc. Catheter with selectively rigidified portion
US4769013A (en) 1982-09-13 1988-09-06 Hydromer, Inc. Bio-effecting medical material and device
NZ205680A (en) 1982-10-01 1986-05-09 Ethicon Inc Glycolide/epsilon-caprolactone copolymers and sterile surgical articles made therefrom
US4603152A (en) 1982-11-05 1986-07-29 Baxter Travenol Laboratories, Inc. Antimicrobial compositions
US4693243A (en) 1983-01-14 1987-09-15 Buras Sharon Y Conduit system for directly administering topical anaesthesia to blocked laryngeal-tracheal areas
US4784647A (en) 1986-07-30 1988-11-15 The Kendal Company Catheter meatal pad device
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4950256A (en) 1988-04-07 1990-08-21 Luther Medical Products, Inc. Non-thrombogenic intravascular time release catheter
JP2683750B2 (en) 1988-06-06 1997-12-03 住友電気工業株式会社 Balloon catheter
DE3821544C2 (en) 1988-06-25 1994-04-28 H Prof Dr Med Just dilatation catheter
US4950239A (en) * 1988-08-09 1990-08-21 Worldwide Medical Plastics Inc. Angioplasty balloons and balloon catheters
US4906244A (en) * 1988-10-04 1990-03-06 Cordis Corporation Balloons for medical devices and fabrication thereof
FR2642474B1 (en) * 1989-01-27 1992-05-15 Floquet Monopole hollow shaft, in particular for motor piston internal combustion, and process for its manufacturing
US5041100A (en) 1989-04-28 1991-08-20 Cordis Corporation Catheter and hydrophilic, friction-reducing coating thereon
US4994033A (en) 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5049131A (en) * 1989-05-31 1991-09-17 Ashridge Ag Balloon catheter
US5026607A (en) 1989-06-23 1991-06-25 C. R. Bard, Inc. Medical apparatus having protective, lubricious coating
US5135516A (en) 1989-12-15 1992-08-04 Boston Scientific Corporation Lubricious antithrombogenic catheters, guidewires and coatings
US5545208A (en) 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
WO1991012779A1 (en) 1990-02-28 1991-09-05 Medtronic, Inc. Intralumenal drug eluting prosthesis
AU7998091A (en) 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5320634A (en) * 1990-07-03 1994-06-14 Interventional Technologies, Inc. Balloon catheter with seated cutting edges
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5500013A (en) 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
JP3053029B2 (en) * 1991-10-08 2000-06-19 テルモ株式会社 Vasodilation catheter balloon
US5282823A (en) 1992-03-19 1994-02-01 Medtronic, Inc. Intravascular radially expandable stent
US5571166A (en) 1992-03-19 1996-11-05 Medtronic, Inc. Method of making an intraluminal stent
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
DE69311847T2 (en) * 1992-04-06 1997-11-13 Terumo Corp balloon catheter
US5500180A (en) * 1992-09-30 1996-03-19 C. R. Bard, Inc. Method of making a distensible dilatation balloon using a block copolymer
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5634901A (en) * 1992-11-02 1997-06-03 Localmed, Inc. Method of using a catheter sleeve
US5578075B1 (en) 1992-11-04 2000-02-08 Daynke Res Inc Minimally invasive bioactivated endoprosthesis for vessel repair
US5449382A (en) 1992-11-04 1995-09-12 Dayton; Michael P. Minimally invasive bioactivated endoprosthesis for vessel repair
EP0689465A1 (en) 1993-03-18 1996-01-03 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
DE69418905D1 (en) * 1993-06-02 1999-07-08 Scimed Life Systems Inc Selective arrangement of friction coatings on balloon catheters
EP0797988B1 (en) 1993-07-19 2009-01-14 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5380299A (en) 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
DE69433506T2 (en) * 1993-10-01 2004-06-24 Boston Scientific Corp., Natick Medical, thermoplastic elastomeric balloons containing
AT189402T (en) * 1994-03-02 2000-02-15 Scimed Life Systems Inc Block copolymer elastomer balloon catheter for
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5891108A (en) * 1994-09-12 1999-04-06 Cordis Corporation Drug delivery stent
WO1996025897A2 (en) 1995-02-22 1996-08-29 Menlo Care, Inc. Covered expanding mesh stent
US5605696A (en) 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6283951B1 (en) * 1996-10-11 2001-09-04 Transvascular, Inc. Systems and methods for delivering drugs to selected locations within the body
US5855546A (en) * 1996-02-29 1999-01-05 Sci-Med Life Systems Perfusion balloon and radioactive wire delivery system
US6099454A (en) * 1996-02-29 2000-08-08 Scimed Life Systems, Inc. Perfusion balloon and radioactive wire delivery system
US6234951B1 (en) * 1996-02-29 2001-05-22 Scimed Life Systems, Inc. Intravascular radiation delivery system
EP1683520B1 (en) * 1996-03-12 2013-11-20 PG-TXL Company, L.P. Water-soluble prodrugs
EP1616563A3 (en) * 1996-05-24 2006-01-25 Angiotech Pharmaceuticals, Inc. Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases
US5830217A (en) * 1996-08-09 1998-11-03 Thomas J. Fogarty Soluble fixation device and method for stent delivery catheters
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
AU8782098A (en) 1997-08-13 1999-03-08 Boston Scientific Limited Loading and release of water-insoluble drugs
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
US6093463A (en) * 1997-12-12 2000-07-25 Intella Interventional Systems, Inc. Medical devices made from improved polymer blends
US6240407B1 (en) * 1998-04-29 2001-05-29 International Business Machines Corp. Method and apparatus for creating an index in a database system
WO2000010622A1 (en) * 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US6733513B2 (en) * 1999-11-04 2004-05-11 Advanced Bioprosthetic Surfaces, Ltd. Balloon catheter having metal balloon and method of making same
US6468297B1 (en) * 1999-02-24 2002-10-22 Cryovascular Systems, Inc. Cryogenically enhanced intravascular interventions
US6432102B2 (en) * 1999-03-15 2002-08-13 Cryovascular Systems, Inc. Cryosurgical fluid supply
US6418448B1 (en) * 1999-12-06 2002-07-09 Shyam Sundar Sarkar Method and apparatus for processing markup language specifications for data and metadata used inside multiple related internet documents to navigate, query and manipulate information from a plurality of object relational databases over the web
US6527740B1 (en) * 1999-12-22 2003-03-04 Advanced Cardiovascular Systems, Inc. Medical regrooming and drug delivery device
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US6602246B1 (en) * 2000-08-18 2003-08-05 Cryovascular Systems, Inc. Cryotherapy method for detecting and treating vulnerable plaque
US6863861B1 (en) * 2000-09-28 2005-03-08 Boston Scientific Scimed, Inc. Process for forming a medical device balloon
US7186237B2 (en) * 2002-02-14 2007-03-06 Avantec Vascular Corporation Ballon catheter for creating a longitudinal channel in a lesion and method
JP4583032B2 (en) * 2002-04-25 2010-11-17 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Apparatus and method for using an expandable guide sheath and the sheath
US7037319B2 (en) * 2002-10-15 2006-05-02 Scimed Life Systems, Inc. Nanotube paper-based medical device
US20060121080A1 (en) * 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
US20040117222A1 (en) * 2002-12-14 2004-06-17 International Business Machines Corporation System and method for evaluating information aggregates by generation of knowledge capital
US7686824B2 (en) * 2003-01-21 2010-03-30 Angioscore, Inc. Apparatus and methods for treating hardened vascular lesions
JP4468943B2 (en) * 2003-03-31 2010-05-26 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ Macrolide crystallization and purification
US7060062B2 (en) * 2003-06-04 2006-06-13 Cryo Vascular Systems, Inc. Controllable pressure cryogenic balloon treatment system and method
US20050025848A1 (en) * 2003-07-30 2005-02-03 Ruey-Fa Huang Air filter shaping mold
US8740844B2 (en) * 2003-08-20 2014-06-03 Boston Scientific Scimed, Inc. Medical device with drug delivery member
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US7070576B2 (en) * 2004-04-30 2006-07-04 Boston Scientific Scimed, Inc. Directional cutting balloon
US7753876B2 (en) * 2004-05-10 2010-07-13 Medtronic Vascular, Inc. Expandable jaw drug delivery catheter
US7758541B2 (en) * 2004-08-17 2010-07-20 Boston Scientific Scimed, Inc. Targeted drug delivery device and method
US20060069385A1 (en) * 2004-09-28 2006-03-30 Scimed Life Systems, Inc. Methods and apparatus for tissue cryotherapy
US7279571B2 (en) * 2004-12-01 2007-10-09 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Methods of preparing pimecrolimus
US7658744B2 (en) * 2004-12-03 2010-02-09 Boston Scientific Scimed, Inc. Multiple balloon catheter
US7580930B2 (en) * 2005-12-27 2009-08-25 Baynote, Inc. Method and apparatus for predicting destinations in a navigation context based upon observed usage patterns
US7698270B2 (en) * 2004-12-29 2010-04-13 Baynote, Inc. Method and apparatus for identifying, extracting, capturing, and leveraging expertise and knowledge
US8221824B2 (en) * 2005-02-03 2012-07-17 Boston Scientific Scimed, Inc. Deforming surface of drug eluting coating to alter drug release profile of a medical device
US20060184191A1 (en) * 2005-02-11 2006-08-17 Boston Scientific Scimed, Inc. Cutting balloon catheter having increased flexibility regions
US8048028B2 (en) * 2005-02-17 2011-11-01 Boston Scientific Scimed, Inc. Reinforced medical balloon
US7527604B2 (en) * 2005-03-09 2009-05-05 Boston Scientific Scimed, Inc. Rotatable multi-port therapeutic delivery device
KR20080008364A (en) * 2005-05-05 2008-01-23 헤모텍 아게 All-over coating of vessel stents
CN1317920C (en) * 2005-06-15 2007-05-23 华为技术有限公司 Service indication message transmitting method under sleeping mode
US20070078413A1 (en) * 2005-08-25 2007-04-05 Stenzel Eric B Medical device having a lubricant
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
US8137735B2 (en) * 2005-11-10 2012-03-20 Allegiance Corporation Elastomeric article with antimicrobial coating
KR100673023B1 (en) * 2005-12-28 2007-01-24 삼성전자주식회사 Semiconductor memory device using pipelined-buffer programming scheme
US9192697B2 (en) * 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
CA2663762A1 (en) * 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
JP2010503486A (en) * 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド Endoprosthesis
US8221783B2 (en) * 2007-09-10 2012-07-17 Boston Scientific Scimed, Inc. Medical devices with triggerable bioadhesive material
US7774125B2 (en) * 2008-08-06 2010-08-10 Fluid Control Products, Inc. Programmable fuel pump control
WO2010030728A2 (en) * 2008-09-12 2010-03-18 Boston Scientific Scimed, Inc. Devices and systems for delivery of therapeutic agents to body lumens
EP3064230B1 (en) * 2009-07-10 2019-04-10 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
WO2011008393A2 (en) * 2009-07-17 2011-01-20 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8424498B2 (en) * 2009-07-23 2013-04-23 Briggs & Stratton Corporation Engine blower scroll
WO2011046902A1 (en) * 2009-10-14 2011-04-21 Boston Scientific Scimed, Inc. Balloon catheter with shape memory sheath for delivery of therapeutic agent
US8366661B2 (en) * 2009-12-18 2013-02-05 Boston Scientific Scimed, Inc. Medical device with expandable body for drug delivery by capsules
EP2519269A1 (en) * 2009-12-30 2012-11-07 Boston Scientific Scimed, Inc. Drug-delivery balloons
WO2011081712A1 (en) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
EP2915556A1 (en) * 2010-01-21 2015-09-09 Boston Scientific Scimed, Inc. Balloon catheters with therapeutic agent in balloon folds and methods of making the same
WO2012054129A1 (en) * 2010-10-18 2012-04-26 Boston Scientific Scimed, Inc. Drug eluting medical device utilizing bioadhesives

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US556922A (en) * 1896-03-24 gilpatrick
US4026296A (en) * 1974-03-19 1977-05-31 Ceskoslovenska Akademie Ved Hydrophilic surgical tubular device
US4186745A (en) * 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
US4515593A (en) * 1981-12-31 1985-05-07 C. R. Bard, Inc. Medical tubing having exterior hydrophilic coating for microbiocide absorption therein and method for using same
US4644936A (en) * 1982-11-19 1987-02-24 Iabp Percutaneous intra-aortic balloon and method for using same
US4589873A (en) * 1984-05-29 1986-05-20 Becton, Dickinson And Company Method of applying a hydrophilic coating to a polymeric substrate and articles prepared thereby
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4796629A (en) * 1987-06-03 1989-01-10 Joseph Grayzel Stiffened dilation balloon catheter device
US6730105B2 (en) * 1988-07-29 2004-05-04 Samuel Shiber Clover leaf shaped tubular medical device
US5091205A (en) * 1989-01-17 1992-02-25 Union Carbide Chemicals & Plastics Technology Corporation Hydrophilic lubricious coatings
US5087244A (en) * 1989-01-31 1992-02-11 C. R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US5616149A (en) * 1990-07-03 1997-04-01 Cedars-Sinai Medical Center Balloon catheter with cutting edge
US5385152A (en) * 1990-11-09 1995-01-31 Boston Scientific Corporation Guidewire for crossing occlusions in blood vessels
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5102402A (en) * 1991-01-04 1992-04-07 Medtronic, Inc. Releasable coatings on balloon catheters
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5302634A (en) * 1992-10-15 1994-04-12 Hoppmann Corporation Cured unsaturated polyester-polyurethane hybrid highly filled resin foams
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5733925A (en) * 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5624411A (en) * 1993-04-26 1997-04-29 Medtronic, Inc. Intravascular stent and method
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5609329A (en) * 1994-06-23 1997-03-11 Itt Automotive Europe Gmbh Vibration damping attachment of a drive unit for windshield wipers
US6048515A (en) * 1994-08-04 2000-04-11 Institut Fur Diagnostikforschung Gmbh Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US6183658B1 (en) * 1996-04-10 2001-02-06 Institut Für Neue Materialien Gem. Gmbh Process for preparing agglomerate-free nanoscalar iron oxide particles with a hydrolysis resistant coating
US6541039B1 (en) * 1997-06-20 2003-04-01 Institut Für Neue Materialien Gem. Gmbh Nanoscale particles having an iron oxide-containing core enveloped by at least two shells
US6355029B1 (en) * 1997-12-02 2002-03-12 Cryovascular Systems, Inc. Apparatus and method for cryogenic inhibition of hyperplasia
US20090069883A1 (en) * 1998-04-14 2009-03-12 Ni Ding Medical device with sponge coating for controlled drug release
US6514245B1 (en) * 1999-03-15 2003-02-04 Cryovascular Systems, Inc. Safety cryotherapy catheter
US6838493B2 (en) * 1999-03-25 2005-01-04 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US6867247B2 (en) * 1999-03-25 2005-03-15 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US6548569B1 (en) * 1999-03-25 2003-04-15 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US6186745B1 (en) * 1999-04-28 2001-02-13 Chemand Corporation Gas pressurized liquid pump with intermediate chamber
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US20070093745A1 (en) * 1999-12-30 2007-04-26 Advanced Cardiovascular Systems, Inc. Medical assembly with transducer for local delivery of a therapeutic substance and method of using same
US20070088246A1 (en) * 1999-12-30 2007-04-19 Advanced Cardiovascular Systems, Inc. Medical assembly with transducer for local delivery of a therapeutic substance and method of using same
US20070083149A1 (en) * 1999-12-30 2007-04-12 Advanced Cardiovascular Systems, Inc. Medical assembly with transducer for local delivery of a therapeutic substance and method of using same
US20040023851A1 (en) * 2000-06-29 2004-02-05 Wolfgang Barnikol Method for the porduction of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross- linking in the presence of chemically non- reacting effectors of the oxygen affinity of the haemoglobin
US7005414B2 (en) * 2000-06-29 2006-02-28 Sanguibiotech Gmbh Synthetic oxygen transport made from cross-linked modified human or porcine haemoglobin with improved properties, method for a preparation thereof from purified material and use thereof
US20020010489A1 (en) * 2000-07-24 2002-01-24 Jeffrey Grayzel Stiffened balloon catheter for dilatation and stenting
US20100049309A1 (en) * 2000-10-31 2010-02-25 Bates Brian L Coated medical device
US20100092540A1 (en) * 2000-12-12 2010-04-15 Boston Scientific Scimed, Inc. Drug delivery compositions and medical devices containing block copolymer
US20070112330A1 (en) * 2001-01-17 2007-05-17 Maria Palasis Therapeutic delivery balloon
US7160317B2 (en) * 2002-01-04 2007-01-09 Boston Scientific Scimed, Inc. Multiple-wing balloon catheter to reduce damage to coated expandable medical implants
US20070106250A1 (en) * 2002-01-22 2007-05-10 Mercator Medsystems Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20070003599A1 (en) * 2002-06-19 2007-01-04 Schwarz Marlene C Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US20060020331A1 (en) * 2002-07-12 2006-01-26 Cook Incorporated Coated medical device
US20040098108A1 (en) * 2002-11-13 2004-05-20 Biotronik Gmbh & Co. Kg Endoprosthesis
US6995661B2 (en) * 2003-07-01 2006-02-07 Nissan Motor Co., Ltd. Vehicular display device
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US20070088255A1 (en) * 2004-03-19 2007-04-19 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20100023108A1 (en) * 2004-03-19 2010-01-28 Toner John L Multiple Drug Delivery From A Balloon And A Prosthesis
US20090088735A1 (en) * 2004-03-23 2009-04-02 Cryocath Technologies Inc. Method and apparatus for inflating and deflating balloon catheters
US20080113081A1 (en) * 2004-04-07 2008-05-15 Abbott Cardiovascular Systems Inc. Methods for Modifying Balloon of a Catheter Assembly
US20060013853A1 (en) * 2004-07-19 2006-01-19 Richard Robert E Medical devices having conductive substrate and covalently bonded coating layer
US20060013854A1 (en) * 2004-07-19 2006-01-19 Strickler Frederick H Medical devices containing copolymers with graft copolymer endblocks for drug delivery
US20060025848A1 (en) * 2004-07-29 2006-02-02 Jan Weber Medical device having a coating layer with structural elements therein and method of making the same
US20060057208A1 (en) * 2004-09-16 2006-03-16 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
US20060058815A1 (en) * 2004-09-16 2006-03-16 Mickley Timothy J Expandable multi-port therapeutic delivery system, device, and method
US20090047414A1 (en) * 2004-09-28 2009-02-19 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US20060079836A1 (en) * 2004-10-12 2006-04-13 Holman Thomas J Reinforced and drug-eluting balloon catheters and methods for making same
US20060085058A1 (en) * 2004-10-20 2006-04-20 Rosenthal Arthur L System and method for delivering a biologically active material to a body lumen
US20070020307A1 (en) * 2005-07-19 2007-01-25 Sheng-Ping Zhong Medical devices containing radiation resistant polymers
US20070067882A1 (en) * 2005-09-21 2007-03-22 Liliana Atanasoska Internal medical devices having polyelectrolyte-containing extruded regions
US20100096781A1 (en) * 2006-01-31 2010-04-22 Abbott Cardiovascular Systems Inc. Method Of Fabricating An Implantable Medical Device Using Gel Extrusion And Charge Induced Orientation
US20090054837A1 (en) * 2006-02-09 2009-02-26 B. Braun Melsungen Ag Coating Method for a Folded Balloon
US20090005849A1 (en) * 2006-03-24 2009-01-01 Syed Faiyaz Ahmed Hossainy Methods and apparatuses for coating a lesion
US20100063585A1 (en) * 2006-07-03 2010-03-11 Hemoteq Ag Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open
US20080027421A1 (en) * 2006-07-27 2008-01-31 Vancelette David W CryoBalloon Treatment for Postpartum Hemorrhage
US20080057102A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
US20080051541A1 (en) * 2006-08-25 2008-02-28 Boston Scientific Scimed, Inc. Medical devices having improved mechanical performance
US20080050415A1 (en) * 2006-08-25 2008-02-28 Boston Scientic Scimed, Inc. Polymeric/ceramic composite materials for use in medical devices
US20080095847A1 (en) * 2006-10-18 2008-04-24 Thierry Glauser Stimulus-release carrier, methods of manufacture and methods of treatment
US20080118544A1 (en) * 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices
US20100074934A1 (en) * 2006-12-13 2010-03-25 Hunter William L Medical implants with a combination of compounds
US20100076542A1 (en) * 2007-02-21 2010-03-25 Eurocor Gmbh Coated expandable system
US20090105686A1 (en) * 2007-06-29 2009-04-23 Xtent, Inc. Adjustable-length drug delivery balloon
US20090018501A1 (en) * 2007-07-13 2009-01-15 Yribarren Travis R Drug Coated Balloon Catheter
US20090024200A1 (en) * 2007-07-20 2009-01-22 Medtronic Vascular, Inc. Drug Eluting Medical Device and Method
US20090076448A1 (en) * 2007-09-17 2009-03-19 Consigny Paul M Methods and devices for eluting agents to a vessel
US20090105687A1 (en) * 2007-10-05 2009-04-23 Angioscore, Inc. Scoring catheter with drug delivery membrane
US20090111960A1 (en) * 2007-10-25 2009-04-30 Boston Scientific Scimed, Inc. Dehydrofluorination and Surface Modification of Fluoropoymers for Drug Delivery Applications
US20090112239A1 (en) * 2007-10-31 2009-04-30 Specialized Vascular Technologies, Inc. Sticky dilatation balloon and methods of using
US20100049294A1 (en) * 2008-06-04 2010-02-25 Zukowski Stanislaw L Controlled deployable medical device and method of making the same
US20100010470A1 (en) * 2008-07-11 2010-01-14 Paragon Intellectual Properties, Llc Nanotube-Reinforced Balloons For Delivering Therapeutic Agents Within Or Beyond The Wall of Blood Vessels, And Methods Of Making And Using Same
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US20100056985A1 (en) * 2008-08-27 2010-03-04 Boston Scientific Scimed, Inc. Electroactive polymer activation system for a medical device
US20100055294A1 (en) * 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100087783A1 (en) * 2008-10-07 2010-04-08 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents to body lumens
US20100125239A1 (en) * 2008-11-14 2010-05-20 Minnow Medical, Inc. Selective Drug Delivery In a Lumen
US20110054396A1 (en) * 2009-08-27 2011-03-03 Boston Scientific Scimed, Inc. Balloon Catheter Devices With Drug-Coated Sheath
US20110054443A1 (en) * 2009-08-31 2011-03-03 Boston Scientific Scimed, Inc. Balloon catheter devices with drug delivery extensions

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8262613B2 (en) 1998-05-18 2012-09-11 Boston Scientific Scimed, Inc. Localized delivery of drug agents
US8177743B2 (en) 1998-05-18 2012-05-15 Boston Scientific Scimed, Inc. Localized delivery of drug agents
US8574191B2 (en) 1998-05-18 2013-11-05 Boston Scientific Scimed, Inc. Localized delivery of drug agents
US9586031B2 (en) 2005-05-11 2017-03-07 Angioscore, Inc. Methods and systems for delivering substances into luminal walls
US10076641B2 (en) 2005-05-11 2018-09-18 The Spectranetics Corporation Methods and systems for delivering substances into luminal walls
US20100063585A1 (en) * 2006-07-03 2010-03-11 Hemoteq Ag Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open
US20080118544A1 (en) * 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) * 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9402935B2 (en) 2006-11-20 2016-08-02 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9314598B2 (en) 2006-11-20 2016-04-19 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9694111B2 (en) 2006-11-20 2017-07-04 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9314552B2 (en) 2006-11-20 2016-04-19 Lutonix, Inc. Drug releasing coatings for medical devices
US9937159B2 (en) 2006-11-20 2018-04-10 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20100209472A1 (en) * 2006-11-20 2010-08-19 Lixiao Wang Drug releasing coatings for medical devices
US9289539B2 (en) 2006-11-20 2016-03-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9289537B2 (en) 2006-11-20 2016-03-22 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
US8932561B2 (en) 2006-11-20 2015-01-13 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9283358B2 (en) 2006-11-20 2016-03-15 Lutonix, Inc. Drug releasing coatings for medical devices
US20080255508A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Drug releasing coatings for medical devices
US20110160658A1 (en) * 2006-11-20 2011-06-30 Lutonix, Inc. Drug releasing coatings for medical devices
US9737691B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9248220B2 (en) 2006-11-20 2016-02-02 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998847B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for medical devices
US9033919B2 (en) 2006-11-20 2015-05-19 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20110159169A1 (en) * 2006-11-20 2011-06-30 Lutonix, Inc. Drug releasing coatings for medical devices
US9757351B2 (en) 2006-11-20 2017-09-12 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
US9757544B2 (en) 2006-11-20 2017-09-12 Lutonix, Inc. Drug releasing coatings for medical devices
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9005161B2 (en) 2006-11-20 2015-04-14 Lutonix, Inc. Drug releasing coatings for medical devices
US9764065B2 (en) 2006-11-20 2017-09-19 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9023371B2 (en) 2006-11-20 2015-05-05 Lutonix, Inc. Drug releasing coatings for medical devices
US20080255509A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8366662B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US8366660B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US8403910B2 (en) 2006-11-20 2013-03-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8404300B2 (en) 2006-11-20 2013-03-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20100179475A1 (en) * 2007-01-21 2010-07-15 Erika Hoffmann Medical product for treating stenosis of body passages and for preventing threatening restenosis
US8597720B2 (en) 2007-01-21 2013-12-03 Hemoteq Ag Medical product for treating stenosis of body passages and for preventing threatening restenosis
US20110098737A1 (en) * 2007-04-13 2011-04-28 Konstantinos Spargias Anti-restenosis drug covered and eluting balloons for valvuloplasty of aortic valve stenosis for the prevention of restenosis
US8187223B2 (en) 2007-05-14 2012-05-29 Eurocor Gmbh Anti-restenosis drug covered and eluting balloons for valvuloplasty of aortic valve stenosis for the prevention of restenosis
US20110021985A1 (en) * 2007-05-14 2011-01-27 Konstantinos Spargias Anti-restenosis drug covered and eluting balloons for valvuloplasty of aortic valve stenosis for the prevention of restenosis
US20110160698A1 (en) * 2007-07-03 2011-06-30 Hemoteq Ag Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US20110238011A1 (en) * 2007-08-03 2011-09-29 Bruno Scheller pharmaceutical-coated medical products, the production thereof and the use thereof
US8608689B2 (en) * 2007-08-03 2013-12-17 Invatec Technology Center Gmbh Pharmaceutical-coated medical products, the production thereof and the use thereof
US9974931B2 (en) 2007-08-03 2018-05-22 Invatec Technology Center Gmbh Pharmaceutical-coated medical products, the production thereof and the use thereof
US9220875B2 (en) 2007-08-03 2015-12-29 Invatec Technology Center Gmbh Pharmaceutical-coated medical products, the production thereof and the use thereof
US20090227948A1 (en) * 2008-03-06 2009-09-10 Boston Scientific Scimed, Inc. Balloon catheter devices with sheath covering
US8114049B2 (en) 2008-03-06 2012-02-14 Boston Scientific Scimed, Inc. Balloon catheter devices with folded balloons
WO2009111709A2 (en) * 2008-03-06 2009-09-11 Boston Scientific Scimed, Inc. Balloon catheter devices with solvent-swellable polymer
WO2009111709A3 (en) * 2008-03-06 2010-07-08 Boston Scientific Scimed, Inc. Balloon catheter devices with solvent-swellable polymer
US8679571B2 (en) * 2008-04-09 2014-03-25 Alexander Rübben Method for producing a bioactive surface on an endoprosthesis or on the balloon of a balloon catheter
US20110092900A1 (en) * 2008-04-09 2011-04-21 Alexander Rubben Method for Producing a Bioactive Surface on an Endoprosthesis or on the Balloon of a Balloon Catheter
US9180485B2 (en) 2008-08-29 2015-11-10 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9770576B2 (en) 2008-08-29 2017-09-26 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8491925B2 (en) 2008-09-15 2013-07-23 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9603973B2 (en) 2008-09-15 2017-03-28 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8563023B2 (en) 2008-09-15 2013-10-22 Covidien Lp Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US10046093B2 (en) 2008-09-15 2018-08-14 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8673332B2 (en) 2008-09-15 2014-03-18 Covidien Lp Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9132211B2 (en) 2008-09-15 2015-09-15 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US10117970B2 (en) 2008-09-15 2018-11-06 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100068170A1 (en) * 2008-09-15 2010-03-18 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9034362B2 (en) 2008-09-15 2015-05-19 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8734825B2 (en) 2008-09-15 2014-05-27 Covidien Lp Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9730820B2 (en) 2008-09-25 2017-08-15 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US8500687B2 (en) 2008-09-25 2013-08-06 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US8049061B2 (en) 2008-09-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
US20100076401A1 (en) * 2008-09-25 2010-03-25 Randolf Von Oepen Expandable Member Having A Covering Formed Of A Fibrous Matrix For Intraluminal Drug Delivery
US8226603B2 (en) 2008-09-25 2012-07-24 Abbott Cardiovascular Systems Inc. Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery
US8076529B2 (en) 2008-09-26 2011-12-13 Abbott Cardiovascular Systems, Inc. Expandable member formed of a fibrous matrix for intraluminal drug delivery
US20100081992A1 (en) * 2008-09-26 2010-04-01 Ehrenreich Kevin J Expandable Member Formed Of A Fibrous Matrix For Intraluminal Drug Delivery
WO2010108678A1 (en) * 2009-03-25 2010-09-30 Karl-Heinz Marx Kit for providing an artificial stomach entrance
US20100285085A1 (en) * 2009-05-07 2010-11-11 Abbott Cardiovascular Systems Inc. Balloon coating with drug transfer control via coating thickness
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US10195311B2 (en) 2009-12-18 2019-02-05 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
US9072812B2 (en) 2010-04-19 2015-07-07 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
US9101684B2 (en) 2010-04-19 2015-08-11 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
US10046092B2 (en) 2010-04-19 2018-08-14 The Spectranetics Corporation Coating formulations for scoring or cutting balloon catheters
US9173977B2 (en) 2010-04-19 2015-11-03 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
US9078951B2 (en) 2010-04-19 2015-07-14 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
US9770536B2 (en) 2010-04-19 2017-09-26 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
US9011896B2 (en) 2010-04-19 2015-04-21 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
US8840542B2 (en) * 2010-06-10 2014-09-23 Myriad Medical, Llc Intracavity balloon catheter
US9821138B2 (en) * 2010-06-10 2017-11-21 Myriad Medical, Llc Intracavity balloon catheter
US20110306825A1 (en) * 2010-06-10 2011-12-15 Myriad Medical LLC Intracavity balloon catheter
US20140357942A1 (en) * 2010-06-10 2014-12-04 Myriad Medical LLC Intracavity balloon catheter
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2012072074A1 (en) * 2010-12-04 2012-06-07 Ruebben Alexander Coating and coating method for the balloon of a balloon catheter, and balloon catheter with coated balloon
US9415193B2 (en) 2011-03-04 2016-08-16 W. L. Gore & Associates, Inc. Eluting medical devices
WO2013015941A1 (en) 2011-07-26 2013-01-31 Medtronic Vascular Inc. Textured dilatation balloon
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9603974B2 (en) 2012-03-27 2017-03-28 Terumo Kabushiki Kaisha Coating composition and medical device
US10045960B2 (en) 2012-03-27 2018-08-14 Terumo Kabushiki Kaisha Coating composition and medical device
US9592322B2 (en) 2012-03-27 2017-03-14 Terumo Kabushiki Kaisha Coating composition and medical device
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
US10173038B2 (en) 2012-09-05 2019-01-08 W. L. Gore & Associates, Inc. Retractable sheath devices, systems, and methods
US9901715B2 (en) 2012-09-05 2018-02-27 W. L. Gore Associates, Inc. Retractable sheath devices, systems, and methods
US10179249B2 (en) 2015-01-08 2019-01-15 Myriad Medical, Llc Intracavity balloon catheter

Also Published As

Publication number Publication date
AT357265T (en) 2007-04-15
DE69935605D1 (en) 2007-05-03
EP1121162B1 (en) 2007-03-21
US20130304029A1 (en) 2013-11-14
US6306166B1 (en) 2001-10-23
EP1800702A2 (en) 2007-06-27
US20060002973A1 (en) 2006-01-05
US20120239001A1 (en) 2012-09-20
DE69935605T2 (en) 2007-11-29
EP1800702A3 (en) 2008-03-05
EP1121162A1 (en) 2001-08-08
WO2000021584A1 (en) 2000-04-20
AU1108800A (en) 2000-05-01
US20020037358A1 (en) 2002-03-28
US20110196340A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
US6379382B1 (en) Stent having cover with drug delivery capability
US6379381B1 (en) Porous prosthesis and a method of depositing substances into the pores
US7622135B2 (en) Coated stent
US7811622B2 (en) Coated implantable medical device
US8961588B2 (en) Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
CN102885665B (en) Temporal intraluminal stent, methods of making and using
US7754272B2 (en) Local drug delivery
EP0565604B1 (en) Catheter for drug delivery system
EP0968013B1 (en) Coated implantable medical device
ES2522277T3 (en) drug eluting stent
EP1454642B1 (en) Stent with phenoxy primer coating
CA2225096C (en) Method of applying drug-release coatings
EP0747069B1 (en) Implantable medical device
US7682387B2 (en) Drug-delivery endovascular stent and method for treating restenosis
US6730064B2 (en) Coated implantable medical device
US7445628B2 (en) Method of treating a patient with a coated implantable medical device
EP2324867B1 (en) Angioplasty balloons drug-coated in an expanded condition
US8753663B2 (en) Drug eluting coatings for medical implants
US5824049A (en) Coated implantable medical device
US5624411A (en) Intravascular stent and method
ES2393639T3 (en) medical product to treat closures of body ducts and prevention of further closures
US6908624B2 (en) Coating for implantable devices and a method of forming the same
US7811317B2 (en) Medical devices for delivering a therapeutic agent and method of preparation
JP4215752B2 (en) The stent coatings and methods to release the drug
US7575632B2 (en) Reflowed drug-polymer coated stent and method thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA

Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:020051/0982

Effective date: 20041222